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Abstract
Introduction: Clustered regularly interspaced short
palindromic repeat and its associated protein (CRISPRCas)-based technologies generate targeted modifications
in host genome by inducing site-specific double-strand
breaks (DSBs) that can serve as a substrate for homologydirected repair (HDR) in both in vitro and in vivo models.
HDR pathway could enhance incorporation of exogenous
DNA templates into the CRISPR-Cas9-mediated DSB site.
Owing to low rate of HDR pathway, the efficiency of accurate
genome editing is diminished. Enhancing the efficiency of
HDR can provide fast, easy, and accurate technologies based
on CRISPR-Cas9 technologies.
Methods: The current study presents an overview of attempts
conducted on the precise genome editing strategies based on
small molecules and modified CRISPR-Cas9 systems.
Results: In order to increase HDR rate in targeted cells, several logical strategies have been
introduced such as generating CRISPR effector chimeric proteins, anti-CRISPR proteins, modified
Cas9 with donor template, and using validated synthetic or natural small molecules for either
inhibiting non-homologous end joining (NHEJ), stimulating HDR, or synchronizing cell cycle.
Recently, high-throughput screening methods have been applied for identification of small
molecules which along with the CRISPR system can regulate precise genome editing through HDR.
Conclusion: The stimulation of HDR components or inhibiting NHEJ can increase the accuracy of
CRISPR-Cas-mediated engineering systems. Generating chimeric programmable endonucleases
provide this opportunity to direct DNA template close proximity of CRISPR-Cas-mediated DSB.
Small molecules and their derivatives can also proficiently block or activate certain DNA repair
pathways and bring up novel perspectives for increasing HDR efficiency, especially in human cells.
Further, high throughput screening of small molecule libraries could result in more discoveries of
promising chemicals that improve HDR efficiency and CRISPR-Cas9 systems.
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Introduction
The progress of programmable nucleases has considerably
augmented the field of precision genome editing and
provided a novel promising avenue for gene therapy
approaches. Until now, four major classes of programmable
nucleases have been established based on introducing
a site-specific double-strand break (DSB); including
i) meganucleases or homing endonucleases which are
achieved from microbial mobile genetic compounds, ii)
zinc finger (ZF) nucleases which are inspired by eukaryotic
transcription factors, iii) transcription activator-like
effector (TALE) nucleases which are originated from
Xanthomonas bacteria, and iv) RNA-guided DNA
endonucleases which are human codon-optimized form
of archaeal and most bacterial adaptive immune systems,
CRISPR-Cas.1,2 CRISPR-Cas systems are categorized into
two basic classes and six types. Because of the diversity
and practicability of CRISPR-Cas9, which is categorized
in class II-type 2, most attractions have been concentrated
on this system and considered as an impressive genome
editing technology in eukaryotic cells. In meganucleases,
ZFN and TALEN, specific DNA binding is developed
by protein-DNA interactions, while Cas9 is recruited to
target DNA sequences by a single-guide RNA (sgRNA)
molecule.3,4 These four categories of genome editing
tools have the common state of generating a site-specific
DSB in the targeted genome (Fig. 1). Naturally occurred

DSBs are repaired by two distinct pathways, error-prone
nonhomologous end-joining (NHEJ) or precise homologydirected repair (HDR).5,6 Since NHEJ naturally is an
error-prone repair pathway, by inhibiting the expression
or function of essential components that are involved in
this pathway, we could ameliorate the nuclease-mediated
HDR efficiency.7,8 In this regard, various small molecules
have been recognized for modulating the efficiency of
genome editing by either suppressing NHEJ or elevating
the activity of HDR pathway. Using small molecules would
develop a simple method that has several advantages for
enhancing precision genome engineering. This review was
focused on the mechanisms and effects of small molecules
in DSB repair to progress the HDR pathway for improving
the efficiency of precision genome editing in both in vivo
and in vitro settings. Furthermore, we aimed to highlight
the recent progress in enhancing HDR efficiency through
using overlapping sequences and also applying novel Cas9
chimeric variants.
DNA repair pathways
By introducing a DSB, several factors such as BRCA1
(breast cancer type 1 susceptibility protein), 53BP1 (p53binding protein1), and receptor-associated protein 80
(RAP80) are recruited to the damaged site and constitute
ionizing radiation induced foci (IRIF). It is elucidated that
a complex network of molecular interactions activating

Fig. 1. The mechanisms and gene editing platforms for repairing DSB. DSBs which are induced by Meganucleases, ZFNs, TALENs, and CRISPR-Cas9
at specific sites could be repaired by NHEJ or HDR pathway. Figure was created with BiorRender (https://biorender.com).
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BRCA1 or 53BP1 derives DSB to HDR or NHEJ repair
pathway, respectively. These two antagonizing factors
permanently are acting contrary to each other at the DSB
site. In order to identify the effect of small molecules to
increase HDR pathway for more efficient and precise gene
editing, an overview of the DNA repair pathways and their
key factors is presented.9
NHEJ pathway
Following the induction of DSB, the first reaction usually
occurs through the NHEJ pathway. In mammalian cells,
almost three quarter of DSBs are repaired via NHEJ and
its defect results in various developmental disorders
and enhances the rate of DSB-related chromosomal
mutagenesis.10 NHEJ is a broad term and commonly
classified into two types:
1. Canonical NHEJ (c-NHEJ): it generally acts in endjoining and for a long time was characterized by its
association with Ku, DNA ligase IV, and dependent
factors.10
2. Non-canonical NHEJ: several homology-independent
repairs triggered by the c-NHEJ dysfunction which
need DNA Ligase I/III and is known as “alternative
NHEJ” (alt-NHEJ/A-NHEJ), “microhomologymediated end joining” (MMEJ), or “backup NHEJ”.10,11
According to distinct DNA ends, NHEJ uses different
strategies and is initiated by phosphorylation of 53BP1
at DSBs through protein kinase ataxia-telangiectasia
mutated (ATM). 53BP1 is a chromatin-binding protein
and an important part of DSB signaling repair in
mammalian cells that during G1 promotes NHEJ. The
basic effector proteins for 53BP1 are DNA polymerase
zeta processivity subunit (REV7), PAX transactivation
domain-interacting protein, and RAP1- interacting factor
1 (RIF1) (Fig. 2A).12 RIF1 is acting together with REV7 for
recruiting a large complex to DSB.13 This large complex
is called shieldin which consists of four components
including REV7, SHLD1 (induces NHEJ while decreasing
the HR by constraining DNA end resection), SHLD2 (an
effector of REV7), and SHLD3.14,15 Furthermore, the core
NHEJ factor recognizes broken ends and keeps them next
to each other so that the other processing factors can be
activated.16
In c-NHEJ, predominantly Ku 80 interacts and
promotes the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs) and creates a permanent complex
that remains bound to the DSB ends.16-18 DNA-PK can
modulate the activity of different enzymes through
autophosphorylation or phosphorylation and lead to DNA
end processing by Artemis which cuts DNA overhangs for
making blunt ends.19 Then, DNA polymerase µ and λ can
add missing nucleotides at the DSB ends.16,20,21 The next
step is ligation of blunt end that is accomplished by Ligase
IV (Lig IV). Ligase IV usually makes a complex with X-ray
repair cross-complementing 4 (XRCC4) and XRCC4-like
factor (XLF) and induces related downstream pathways

(Fig. 2B).22
Alt-NHEJ pathway is generally active during the S and
G2 phases of the cell cycle and repairs DNA DSBs through
microhomology (MH)-mediated end joining (MMEJ)
(Fig. 2C).23 With regard to the annealing of the flanking
MHs, MMEJ is classified into three distinct steps: preannealing, annealing, and post-annealing.24 The initial
step starts from end resection to subject MHs flanking
DSBs through joining of poly [ADP-ribose] polymerase 1
(PARP1) to DSB ends for facilitating the resection factors
[BRCA1/CtIP and MRN complex].25,26 Intermediate
annealing is reclaimed by the XPF/ERCC1 structurespecific nuclease complex, which is similar to XRCC4 in
c-NHEJ. Then, this complex cuts the non-homologous
ends and generates 3’- hydroxyl overhang that is desirable
for developing by DNA polymerase. Finally, the DNA
ligation is catalyzed by Ligase II and III.27
Homology-directed repair (HDR) pathway
HDR, as a constant repair mechanism, comes into action
in the S- or G2-phase and needs homologous DNA
sequences. BRCA1 by suppressing 53BP1, is a pivotal
initiating factor for HDR. Therefore, various inner and
outer factors are involved in this case such as tudorinteracting repair regulator (TIRR) which is able to mask
the H4K20me2 binding surface (a specific target for
53BP1).28 It is reported that overexpression of TIRR leads
to 53BP1 reduction at the DSB site through competing
with RIF1 to bind 53BP1.28,29 Furthermore, the special
complex of MRN along with BRCA1 could identify
dsDNA and create a 15–20 bp nick from the 5′-ends of
the DSB.30 MRE11 is an Mn2+ dependent endonuclease
that nicks the DNA upstream from the break site and
involves in DNA DSB repair homologous recombination
for maintenance of telomere (Fig. 2A, D).31,32 SCAI is
a related protein to induce separation of 53BP1-RIF1.
Dramatically the relation of SCAI-RIF1 leads to some of
the BRCA1 activity. Hence, a great number of HR-factors
such as BRCA1, MRN, CtIP, and so on are inhibited by
knocking out of SCAI.29,33 A deubiquitinating enzyme
(DUB), POH1, increases the removal of 53BP1 from the
damaged locus by preparing interaction between RAP80
and the BRCA1 BRCT domain.34 This enzyme is a part
of proteasome that can neutralize RNF8/RNF168 (E3
ubiquitin ligases)-dependent ubiquitination activity.29,34,35
As above mentioned, the non-canonical NHEJ pathway is
extremely complicated and needs numerous biochemical
factors. Interestingly, HDR and A-NHEJ have a similar
initial steps. However, it is not elucidated how these two
repair pathways are segregated later.
The initiation of HDR is continued by a two-step end
processing. First, it starts with the MRN complex and the
CtIP nucleases that bind to the DNA DSB and second,
in order to create longer 3′-ends, the second stage for
deep resection is occurred by EXO1 and SGS1-DNA2
nucleases.36,37 The impermanent single-stranded DNA
BioImpacts, 2022, 12(4), 371-391
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(ssDNA) overhang needs to be concealed by replication
protein A (RPA) to be protected from exonuclease
activities. Then, Rad51 replaces heterotrimeric RPA
and for simplifying a quest for a homologous donor,
generates a nucleoprotein presynaptic filament.38,39 The
3′ DNA filament will be coated with many proteins,
and then attacks homologous duplex DNA to develop
the D-loop structure as an exchange intermediate. The
D-loop structures are used for the synthesis of identical
DNA sequences.34,40,41 The second end joins the D-loop
and starts the development of a double Holliday Junction
(HJ) structure.42 Indeed, 53BP1 and BRCA1- mediated
mechanisms are complex systems that many factors
and several antagonized points are involved in their
inviolability. In this line, a plethora of targets exists for
manipulating the efficacy of the HDR pathway.
Single-strand annealing (SSA) is an important subtype
of HDR because of its specific mechanism. This pathway is
observed when DSBs occur between two repeat sequences
(Fig. 2E).43 SSA in terms of homological loci is similar to
MMEJ. Although the applied mechanism is the same for
both of them, the involving proteins in SSA are similar to
HDR.40,41

Importance of small molecules in DNA repair pathways
Certain DNA repair pathways could be successfully
activated or blocked by small-molecule compounds.44
During the past decade, multiple studies have shown
that small molecules are a straightforward strategy
for increasing precision genome engineering.7 Several
advantages are mentioned for small molecules such
as their high penetrant effects that lead to a rapid and
controlled response. In addition, easy titration of small
molecules provides optimal concentrations of inhibitors
for delivering to the cell with extremely successful
consequences.45 The pharmacological approach to
obtain a functional small-molecule usually contains: i)
screening a library of chemical compounds to recognize
lead scaffolds; ii) examining substitution places of the
small molecule in terms of medicinal chemistry because
replacements may result in modifications in specificity
or sensitivity; and iii) deriving additional formatives for
optimizing the efficacy of the small molecule. Generally,
pharmacological procedures have been successful for
recognizing various classes of potent inhibitor proteins
such as proteases, nuclear hormone receptors, kinases,
channels, and G protein-coupled receptors. Several

Fig. 2. The interaction of repair pathways at the DNA break site in mammals and comparison of c-NHEJ, a-NHEJ, HDR, and SSA mechanisms. (A)
c-NHEJ key factor (53BP1) and HDR key factor (BRCA1) are motivated by complex interactions. (B) For DSB repair the first pathway choice in mammalian
cells is NHEJ which is occurred in all cell cycle phases. When in DSB the terminuses are preserved from the incision and then ligated, NHEJ is promoted. (C)
The microhomologous sequences which are adjacent to DSB are annealed in alt-NHEJ pathway. (D) HDR repair pathway employs a repair template such as
sister chromatid to reliably amend the DSB. (E) SSA is a DSB repair pathway for fixing DSB by annealing lengthy homologous sequences at flanking sites.
Figure was created with BiorRender (https://biorender.com).
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efforts have been established to chemically scale up the
efficiency of HDR pathway.46 The nuclear domain knockin screening that is described by multiple studies develops
an idea that indicting simple means of quickly appraising
small molecules that can elevate the efficiency of HDR is
mediated by CRISPR-Cas9 technology.7,45 For example,
Yu et al applied a high-throughput chemical screening
test based on the reporter system for exploiting HDR
efficiency. It was reported that using the candidate small
molecules could increased the efficiency of HDR for large
fragments and point mutations 3- and 9-fold, respectively.
L755507 and Brefeldin A were two small molecules whose
positive effects were elucidated in this high-throughput
chemical screening test. Moreover, many small molecules
that inhibit HDR and could elevate indel mutations
mediated by NHEJ were also reported.7 Therefore,

research to screen other small molecule libraries has been
going on and introduced a strategy that simplifies precise
CRISPR-Cas gene editing for clinical applications and
biomedical experiments.
Inhibition of key NHEJ factors
Recently numerous small molecules have been validated
to enhance the efficiency of HDR, which is mediated
by CRISPR-Cas9 in various cells.46 Several studies have
shown that DSBs, introduced by CRISPR-Cas9 system, are
mostly repaired by NHEJ. Hence, it seems reasonable, by
inhibiting the key enzymes of NHEJ, the HDR efficiency
would be increased. A comprehensive list of small
molecules with NHEJ inhibitory effects is summarized in
Table 1.

Table 1. Small molecules involved in inhibition of NHEJ and stimulation of HDR

Targeted
protein

Small
molecule

Cell type

Locus/Gene

Dose of
substance

Study
method

Observed effects

Ref.

Inhibiting NHEJ
DNA-PK

Ku complex
Ku complex

Nu7026

iPSC

Nu7026
Nu7026
Nu7026
Nu7026
Nu7026
Nu7026
NU7026

HEK293
K562
CD4+ T
CD34+ progenitor cells
HEK293
HepG2-1.1merHBV
K562

CALD1
KATNA1
SLITRK1
HPRT
HPRT
HPRT
HPRT
GFP
HBV genotype D
GFP

20 µM

In vitro

20 µM
20 µM
20 µM
20 µM
30 µM
7.5 µM
3 µM

In vitro
In vitro
In vitro
In vitro
In vitro
In vitro
In vitro

1.5
2.6
2.5-fold increase in HDR
3.0-fold increase in HDR
4.0-fold increase in HDR
3.0-fold increase in HDR
1.7-fold increase in HDR
2.5 -fold increase in HDR
Increased A-NHEJ
Modest increase in HDR (1.1-fold)

46

46
46
46
46
47
48
49

NU7441

K562

GFP

3 µM

In vitro

2.4-fold increase in HDR (8.6% to
21.5%)

NU7441

HSPC

PTPRC

3 µM

In vitro

2-fold increase in HDR (12 to 24%)

49

NU7441

iPSCs

CTNNB1

2 µM

In vivo

Modest increase in HDR 1.2(16%
vs. 13% in control)

50

NU7441
NU7441
KU-0060648
M3814
STL127705
STL127705

HEK293/ TRL
MEFs
HEK293/ TRL
409B2 hiPSC1
SF-767 cells
PrEC cells

GFP
TP53
GFP
FRMD7

2 µM
2 µM
250 nM
2 µM
2.5 µM
2.5 µM

In vitro
In vitro
In vitro
In vitro
In vitro
In vitro

2-fold increase in HDR
10- fold increase in HDR
2.1-fold increase in HDR
Increased in HDR (18% to 81% )
Not tested
Not tested

hiPSC

51
51
51
52
53
53

4-fold increase in HDR by CRISPRCas9 and CRISPR-Cpf1- mediated
targeting
3.5-fold increase in HDR by
CRISPR-Cpf1 5-fold increase by
CRISPR-Cas-mediated targeting

54

1 µM

In vitro

CALD1
KATNA1
SLITRK1

0.01 µM

In vitro

1.5
2.2
1.8-fold increase in HDR

46

iPSCs

CALD1
KATNA1
SLITRK1

0.01 µM
20µM

In vitro

1.8
2.5
3.1-fold increase in HDR

46

SCR-7

HCT-116 cells

AAVS1

10 µM

In vitro
In vivo

SCR-7

Mouse embryos

lgkc

1000 µM

In vitro

ATR2

VE-822

ATM

Trichostatin A

iPSCs

CRISPY mix

Trichostatin A
Nu7026

Ligation

OCT4
ALBUMIN

49

1.7-fold increase in β-catenin gene
(14.6% vs. 8.4% in control %)
4.5- fold increase in HDR (22.7%
vs. 5% in control)

BioImpacts, 2022, 12(4), 371-391

55

8

375

Shams et al
Table 1. Continued

Targeted
protein

Small
molecule

Cell type

Locus/Gene

Dose of
substance

Study
method

Observed effects

Ref.

SCR-7

Mouse embryos

Kell

1000 µM

In vitro

2.2-fold increase in HDR (59.3 %
vs. 26.6% in control)

8

SCR-7

CHO cells

COSMC FUT8

0.1–20 µM +
10 mM LiCl

In vitro

None

56

SCR7

iPSCs

CALD1
KATNA1
SLITRK1

1 µM

In vitro

None

46

Actb

1 µM

In vitro

Promoted Tild-CRISPR-mediated
knock-in

57

1-10 µM

In vitro

Modest fold increase in HDR
(13.6% vs. 12.5 in control %)

58

SCR-7

Mouse ESCs3

SCR-7

HEK293T cells

MALAT1

SCR-7

Murine zygotes

Tex15

50 µM

In vivo

9.7-fold increase in HDR (56.2% vs.
5.8% in control)

59

SCR-7

HEK293A

LMNA

1μM

In vitro

Modest increase in HDR (11.7% vs.
9.9% in control)

45

SCR-7

Porcine fetal fibroblasts

GFP

200,50 µM

In vitro

2-fold increase in HDR (11.2% vs.
5.6% in control)

60

SCR-7

Porcine fetal fibroblasts

ROSA26

100 µM

In vitro

1.9-fold increase in HDR with
neomycin selection (49.7%
vs.26.2% in control)

60

SCR-7

Zebrafish embryos

Ybx1S82A

20µM

In vivo

3.6 -fold increase in HDR (55% vs.
15% in control )

61

SCR-7

COS-7 cells

PAH

In vitro

2.5-fold increase in HDR (22.1% vs.
8.8% in control )

62

SCR-7

HEK293T cells

GFP

1 µM

In vitro

1.8- fold increase in HDR

51

CRISPY mix

SCR-7
KU-0060648

HEK293T cells

GFP

1 µM
250 µM

In vitro

2.9- fold increase in HDR

51

CRISPY mix

SCR-7
NU7441

HEK293T cells

GFP

1 µM
2 µM

In vitro

3- fold increase in HDR

51

15 µM

Stimulating HDR
RAD51

1

RS-1

K562

GFP

3 µM

In vitro

2.2-fold increase in HDR (17.6% vs.
8.6% in control)

49

RS-1

Zebrafish embryos

eBFP2

30 µM

In vivo

1.5-fold increase in HDR by Cas9mediated

63

RS-1

U2OS

LMNA

10 µM

In vitro

Modest increase in HDR (2.5% vs.
1.9 in control %)

45

RS-1

HEK293 A cells

LMNA

10 µM

In vitro

6-fold increase in HDR
(21% vs. 3.5 in control %)

45

RS-1

HEK293 A cells

PML

10 µM

In vitro

4- fold increase in HDR(40% vs.
10% in control %)

45

RS-1

Zebrafish embryos

Ybx1S82A

20 µM

In vivo

1.6- fold increase in HDR (24% vs.
15% in control %)

RS-1

iPSCs

CALD1
KATNA1
SLITRK1

1 µM

In vitro

None

RS-1

iPSCs

CTNNB1
PRDM14

10 µM

In vivo

None

RS-1

Bovine zygotes

XbaI

7.5 µM

In vitro

2.1-fold increase in HDR (53% vs.
25% in control %)

Human iPS cells; 2 ATM and Rad3-related; 3Embryonic stem cells.
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DNA-PK
The first component of NHEJ for recognizing and binding
to DSBs is DNA-PK. This holoenzyme is a compound of
a 460 kD catalytic subunit, DNA-PKcs, Ku70, and Ku80
subunits (regulatory heterodimer). It has been revealed
that recruiting libraries of these compounds could
develop several molecules for inhibiting DNA-PK activity.
Since NHEJ repair relies on DNA-PK activity, detrimental
genetic mutations or using small molecules with inhibitory
effects on DNA-PK could result in an increase in HDR
occurrence. Targeting the ATP binding site of DNA-PK
by small molecules is the most successful procedure for
inhibiting this pivotal factor in NHEJ. For the phosphate
transfer reaction by irreversible alkylation, lysine 802 in
DNA-PKcs active site could be targeted by Wortmannin
which is a small molecule with an inhibitory effect on
PI3 kinases. Wortmannin naturally originated from a
furanosteroid metabolite from Penicillium funiculosum.
Although the experimental efficacy of wortmannin has
been proven, multiple obstacles such as poor solubility,
lack of specificity, and in vivo toxicity restrict its clinical
application.65 LY294002 is a competitive inhibitor of
DNA-PK and PI3 kinase. It is reversibly able to interact
with the kinase domain. This small molecule is originated
from the plant flavonoid as a morpholine derivative.
LY294002 leads to a delay in DSB repair, which might
attribute largely to inhibition of DNA-PK. Because of fastmetabolic clearance and in vivo toxicity, it is impossible
to clinically evaluate the effects of LY294002. However,
LY294002 has been demonstrated to be a productive
and leading compound which by acquiring biochemical
alterations, a series of recombinant compounds with more
appropriate features would be established. A modified
form of LY294002 is NU7026 which is more selective for
DNA-PK compared to other PI3 kinases such as ATM
and ATR that had an IC50 of 13µM for PI3K, 0.23µM for
DNA-PK, and >100µM for ATR or ATM. Nonetheless,
for obtaining potent and selective DNA-PK inhibitors,
the substitution of 2-morpholin-4-yl and alteration of
thiopyran-4-ones or pyran-4-ones is proposed.66 NU7441
is another agent that originates from LY294002 with
remarkably improved potency compared to NU7026.
It strongly inhibits DNA-PK with an IC50 of 0.3 µM in
cell lines. Tavecchio et al reported that in the presence
of ionizing radiation (IR) and NU7026, the induced
DSBs continued for a long time and the activeness of
HR enhanced moderately.67 Development of NU7441
continues and leads to the identification of KU-0060648,
which has greater solubility against DNA-PK and is a
binary inhibitor of PI-3K and DNA-PK in vitro. Munck
et al showed that the inhibitory effect of KU-0060648 on
DNA-PK in MCF7 is approximately 8-fold higher than
in SW620 cells.68 Other non-toxic compounds based on
the LY294002 structure, such as IC86621, IC87102, and
IC87361 have expanded the application of compounds
derived from this small molecul.66 NU7026, NU7441, and

KU-0060648 provide high efficiency for improving the
HDR rate in genome editing compared to other DNAPK inhibitors. Previously it was demonstrated that the
efficiency of knock-in is augmented by NU7026 in hiPSCs.
Likewise, this small molecule is a crucial complex in the
NHEJ pathway. Riesenberg et al reported that NU7026
was the only small molecule that clearly increased the
efficiency of targeted gene fragment insertion in HEK293
(by 3-fold), K562 cells (by 4-fold), CD4+ T cell (by 3-fold),
and CD34+ progenitor cells (by 1.7-fold).46 Besides, Robert
et al described that treating HEK293 TLR with NU7441
and KU-0060648 leads to, respectively, a 3- and 4-fold
increase in HDR efficiency, and an approximately 2-fold
reduction in the NHEJ repair. They also demonstrated that
oligonucleotide-mediated HDR, as a repair template, at
the endogenous site could be stimulated by both NU7441
and KU-0060648. Therefore the results of using additional
DNA-PK inhibitors lead to compatibility with the Cas9
editing system.51 Moreover, combining proteins or siRNA
along with small molecules could be more effective. They
showed that Adenovirus 4 (Ad4), E1B55K and E4orf6
proteins with KU-0060648 or NU7441 could induce HDR
approximately up to 5-fold in HEK293T cells.51 Aksoy et
al reported the initial application of NU7441 as a powerful
HDR enhancer with an increase in HDR efficiency up to
13.4-fold in zebrafish embryos genome-edited by CRISPRCas9 system.63 Recently, M3814 was introduced as a new
selective pharmacological inhibitor of DNA-PK which
has not been applied in genome editing before. M3814 is
a highly potent molecule that showed acceptable activity
in preclinical models. This molecule was also introduced
as a practical therapeutic strategy in cancer treatment.69
For instance, in combination with cisplatin and etoposide,
M3814 has represented promising activity in lung cancer
in vivo models.70 On the other hand, Sun et al showed
that the repair of radiation-induced DSBs could fruitfully
be shut off by M3814. Furthermore, this small molecule
can efficiently increase activation and phosphorylation
of p53.71 Additionally, M3814 was used in phase Ib/II
clinical trials for the treatment of several cancers such as
rectal cancer (NCT03770689) and small cell lung cancer
(NCT03116971). Riesenberg et al used M3814 in genome
editing for the first time. It was used to transiently inhibit
NHEJ and increase HDR from 18% to 81% in K562 cells
while demonstrating moderate toxicity.52 In line with these
premises, M3814 could be applied in gene therapy, where
high HDR performances may be required to achieve
therapeutic goals. VE-822, a specific inhibitor of ATR,
that was recently used by Ma et al enhances the efficiency
of HDR efficiency in combination with a plasmid donor
and a ssODN donor by 5.9-fold and 3-fold, respectively.
Furthermore, combining AZD-7762, a specific inhibitor
of checkpoint kinase CHEK1 and the ATR inhibitor could
remarkably boost the specificity of CRISPR-Cas9 genome
editing.54

BioImpacts, 2022, 12(4), 371-391

377

Shams et al

Ku70/80 complex
The heterodimeric Ku complex is the most logical choice
for inhibition of the entire NHEJ process. This protein
shows a great binding affinity for dsDNA termini and
has a ring-like shape which upon binding DNA, cannot
tolerate any substantial structural variation. This ring-like
structure leads to the interaction of Ku protein with DNA
that is crucial for the activation of kinase and in this regard,
it is also an appropriate target for intervention.65 Although
in the initiation of the NHEJ pathway, Ku has a key role,
limited studies have addressed this protein and only one
inhibitor of Ku protein was obtained (STL127705).44 For
the first time, Weterings et al in the low micro-molar range,
confirmed the compound with Ku-inhibitory activity.
However, the ability of this molecule to block NHEJ is not
well documented.53 Recently, Gavande et al represented
novel small molecule inhibitors that bind to the Ku–DNA
protein to block the protein–DNA interaction. These
specific Ku–DNA binding inhibitors (Ku-DBi’s) block KuDNA interaction, the activity of DNA-PK kinase, and in
vitro NHEJ by directly binding to Ku protein. Moreover,
Ku-DBi’s increase the cellular activity of radiomimetic
agents and IR.72
DNA-end processing enzymes
The DNA-end processing step in NHEJ is an attractive issue
for studying and various nucleic acid enzymes involved in
this step are recognized. However, no remarkable effort has
been made to validate these enzymes as potential targets.
Because of the hardness in purifying the proteins and
the requirements for complex assay, no inhibiting agent
has been identified for Artemis as DNA-PK dependent
endonuclease.
Polynucleotide
kinase/phosphatase
(PNKP) can bind to DNA 5'-end and dephosphorylate
DNA 3'-end in the NHEJ pathway. Furthermore, PNKP
is essential for both single- and DSB repairs. Therefore
identifying small molecule inhibitors for this enzyme
seems very useful to regulate NHEJ.65 Five compounds
with remarkable inhibitory effect on PNKP phosphatase
activity was recognized by Freschauf et al.73 A12B4C3 is
one of these compounds with IC50 value of 0.06 Mmol/L,
showing the highest noncompetitive inhibitory effect on
phosphatase activity of PNKP by obstructing its secondary
structure.73 There is no more information about the effect
of this inhibitor on NHEJ pathway. Therefore, identifying
and introducing additional small molecules for inhibition
of DNA-end processing enzyme is required.
Ligation process enzymes
The ligation process of NHEJ particularly the DNA ligase
enzyme is an attractive target for regulating NHEJ. L189
was the first recognized compound by Chen et al for
inhibiting the DNA ligase.74 Although this molecule had
a poor specificity, it represented a promising inhibitory
effect on Ligase I, III, and IV.74 One of the L189 derivatives,
SCR7, was synthesized as a more specific and putative
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inhibitor of NHEJ. This compound blocks end-joining
through intervening with the connection of Ligase IV
to DNA, consequently, the accumulation of DSBs within
the cells and increasing cytotoxicity were accrued.75 Most
investigations showed a considerable dose-dependent
decline of NHEJ in various models, both in vitro and in
vivo. Some groups demonstrated that a modest increasing
efficiency of HDR-mediated gene insertion could be
achieved by combining SCR7 with enhancing genome
engineering techniques such as synchronization or
optimized Cas9 delivery.76,77 The SCR7 effects in CRISPRCas9 experiments and subsequently the increased HDR
rate was demonstrated in various cells such as HEK293T
(by 2-fold),51 A549 (by 3-fold), MelJuSo (by 19-fold),8 and
HEK293 (by 5-fold).77 However, complete inefficiencies
of Scr7 or slightly increasing the HDR rate were reported
in cells such as human embryonic stem cells,78 iPSCs,50
Porcine fetal fibroblasts,79 rabbit embryos,80 HEK293A,45
and CHO cells.56 Srivastava et al demonstrated that the
reason for these inconsistency effects of SCR7 is related
to different expressions of LigIV in various cell cultures,
and the cells with high expression level of LigIV are
more sensitive to SCR7.40, 75 Contrary to the results for
SCR7 reported by Raghavan et al, others discovered
several differences in the original structure of SCR7.75, 81
Greco et al performed a broad investigation on structural
determination of SCR7 and confirmed the structure of
SCR7-R and its closely related derivative, SCR7-G, that is
generated by the synthesis protocol described by Raghavan
(Fig. 3).81 They found that commercially available SCR7
(SCR7-X) structurally is similar to SCR7-G. Indeed,
both SCR7-G and SCR7-R have weak inhibitory effects
on LigIV while providing stronger activity with regard
to LigI and LigIII/XRCC1. Hence, they suggested that
the effect of increasing HDR by SCR7, particularly at a
low concentration (about <200 uM) is occurred by other
mechanisms.81 Despite these differences, it is confirmed
that at the defined concentration of SCR7-X/SCR7-G (1
µM), the efficiency of CRISPR-Cas9 gene editing could
be enhanced.75,81 By focusing on embryos, it was observed
that SCR7 increases HDR efficiency in the mouse
embryos,8,82 but not in the rabbit embryos.80 Likewise,
Singh et al reported the increased rate of HDR (by 10-fold)
in murine zygotes82 and Maruyama et al also reported
correcting homozygous editing in addition to increased
HDR efficiency.8 In order to improve the efficiency of
SCR7, combining this small molecule with other NHEJ
inhibitors is a logical suggestion. Chu et al showed that
using Scr7 simultaneously with XRCC6 and LIG4 knockout models resulted in 5-fold increase in HDR efficiency,77
while others have not observed such increasing effects.83
Moreover, it was determined that a combination of SCR7
with KU-0060648 or NU7441 in HEK293 cell (CRISPY
mix) could stimulate HDR efficiency by 3-fold.51 In
general, inhibiting the key factors of NHEJ causes the
unrepaired DSB accumulation in the cell, as a result,
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Fig. 3. Different structures of the Ligase IV inhibitor, SCR7. (A) L189 as a human DNA ligase inhibitor. (B) Less stable parental SCR7 reported by
Srivastava et al can get autocyclized into a more stable form (SCR7-R). (C) Having the same molecular weight, number of protons, molecular mass, and
melting point. Pending dehydrogenation, SCR7-R gets converted into SCR7-G (D), the compound sold as SCR7 by XcessBio (SCR7-X), possessing a
different molecular weight, number of protons, molecular mass, and melting point.

apoptosis and cell death would be increased. In this line,
this approach could increase cytotoxicity and should be
applied with precaution.
Supporting HDR key factors
HDR is a substantial pathway for certifying the precise
repair of nicks and DSBs. Therefore, another way for
changing DNA repair from NHEJ to HDR is instigation
of HDR key components.84 A comprehensive list of small
molecules, which are involved in stimulation of HDR, is
represented in Table 1.
Rad51, a factor for exchanging DNA strands, is
the central and target point for HDR, and by the
accumulation of other proteins on ssDNA, it forms
presynaptic filaments.85 Indeed, it has an extensive role in
the formation of a RAD51–ssDNA filament by replacing
RPA, and interactingwith ssDNA. In order to enhance
RAD51 binding to DNA, Jayathilaka et al developed a
high-throughput microplate-based assay for evaluation
of the filament formation of hRAD51 on ssDNA.86 By
applying this approach, a library with 10,000 compounds
was screened that resulted in the recognition of a small
molecule called RAD51-stimulatory compound 1 (RS1).87 In different biochemical conditions, RAD51 binding
could be enhanced by RS-1. After the ultrastructural assay
of developed filaments on ssDNA, it was determined
that RS-1 could increase protein–DNA complex lengths
and the pitch of helical filament turns. Moreover, the
experiment of RS-1 by salt titration demonstrated
increasing filament stability. According to experiments,

RS-1 depending on the condition can stimulate the
activity of RAD51-mediated homologous strand (D-loop)
at least 5- to 11-fold.86 Actually, the organization of active
presynaptic filaments is boosted by RS-1 that can increase
the homologous recombination activity of RAD51 by
about 2-fold.86 Therefore, Jayathilaka et al showed that
RS-1 could motivate the performance of homologous
recombination repair; thereby, it is functional in both
medical and research settings.86 In research, RS-1 in
HEK293A could increase the HDR rate up to 6-fold and
4-fold by using Cas9 and Cas9 nickase, respectively.88 Song
et al reported impressive results in both in vivo and in vitro.
They indicated that RS-1 enhanced the HDR rate by 6-fold
for the ROSA26-like locus (RLL) in vitro and by 2.4-fold
for the CFTR gene in rabbit embryos.80 Combinatorial
treatment using RS-1 and NU7441 in zebrafish embryos63
or applying both SCR7 and RS-1 with/without L755507
in HEK293 cells did not show a significant increase
in HDR efficiency compared to RS1 alone.45 Similar
results were also observed when L755507, SCR7, and
RS-1 were used together in stem cells.46 However, in one
report it was revealed that the combination of SCR7 and
RS1 increased HDR efficiency up to 74% in zebrafish
embryos.61 Unfortunately, contradictory outcomes have
been achieved for both small drugs, SCR7 and RS-1, in
various cell types. In this regard, the highest efficiency of
RS1 was observed in bovine zygotes.64 In addition to RS-1,
MLN4924 is another small molecule for stimulating HDR.
It is a Nedd8 activating enzyme (NAE) inhibitor that can
block the neddylation of CtIP and result in a rise in the
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extent of DNA end cutting at strand breaks. MLN4924
through inhibition of neddylation artificially increases
the CtIP expression level which in turn promotes HDR
efficiency.46 Although the effect of some small molecules
was unknown or was observed in different stages of DNA
repair (multiple effects), they could provide increasing
HDR efficiency. A comprehensive list of small molecules
with multiple or unknown effects is summarized in
Table 2.
Synchronizing cell-cycle
HDR and NHEJ are dominant repair pathways at different
phases of cell-cycle. Synchronization of cells is reversible
and provides to be widely used while it does not affect the
pluripotency of stem cells. One approach for increasing
HDR efficiency in CRISPR-Cas9 genome-edited cells is
using small molecules for cell-cycle synchronization. In
this line, various small molecules have been introduced
for arresting cell cycle at different phases. For example,
Lovastatin hampers cell cycle at early G1 and partly at G2/M
phase; L-mimosine, Hydroxyurea (HU), Aphidicolin,
Dideoxycytidine (ddC), and Thymidine could apprehend
cells at G1-S frontier before starting the DNA replication;
and antineoplastic microtubule polymerization inhibitor
(Nocodazole), Indirubin-3-monoxime, Vinblastine,
and ABT block cell cycle at G2/M phase. Since HDR is
restricted to the S and G2 phases, synchronizing the cell
cycle in these two stages might be beneficial for increasing
the HDR rate. Some small molecules arrest cells at the
G1-S border before the onset of DNA replication by
inhibiting the effective enzyme of A-NHEJ pathways.
Some molecules arrest cells at the G2/M phase, thereby
providing modulation of HDR-mediated Cas9 genomeediting through cell cycle synchronization.
Arrest at the G1-S border
Aphidicolin is a reversible chemical inhibitor that inhibits
the DNA polymerase-α, δ, and blocks cell cycle in S phase.89
Several reports have estimated that Aphidicolin increases
HDR rate in HCT116 cells, embryonic stem cells (ESCs),
and primary neonatal fibroblasts by 3-fold, 1.6-fold, and
1.3-fold, respectively.90,91 Furthermore, the frequency
of HDR was enhanced with thymidine treatment in H9
human embryonic stem cells (hES) and human primary
neonatal fibroblasts (neoFB).91 It is determined that HU
arrests cell cycle in S-phase by inhibiting ribonucleotide
reductase enzyme. Tsakraklides et al reported that cells,
by using HU before transformation process in five yeast
strains, were synchronized in S-phase and the efficiency
of gene targeting was increased.92 2′,3′-dideoxycytidine is
another promising small molecule that slows down the
replication fork movement and results in S-phase extension.
Brachman et al reported that this small molecule develops
the S phase up to 70% and increases HDR rate by 3-fold
in DLD-1 cells.93 Recently, XL413, a new small molecule
targeting cell division cycle 7(CDC7) plays an important
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role during initiation of DNA replication, arrests primary
T cells in S phase, and enhances the HDR efficiency up
to 3.5-fold.94 According to these observations, designing
experiments for identifying the most optimal small
molecules is necessary because different small molecules
that intervene in cell synchronization have varied effects
on various cells.
Arrest at G2/M
G2/M phase is another crucial hot spot in cell cycle for
being regulated by small molecules to increase HDR
efficiency. Lin et al reported that Nocodazole is able to
arrest cell cycle at specific phases and increase HDR rate
with CRISPR-Cas9 by 1.4-6-fold in HEK293T cells.91
By applying Nocodazole or ABT-751, Yang et al could
successfully enhance HDR-mediated knock-ins by 3- to
6-fold.78 The treatment with Nocodazole reverses the
synchronization of cell cycle in different cell models
such as iPSCs and human pluripotent stem cells (hPSCs),
50,78,91
albeit not observed in ESCs and primary neonatal
fibroblasts.91 Combinatorial treatment with CCND1,
a cell cycle regulatory subunit in G1/S transition, and
Nocodazole increased the HDR efficiency up to 30% in
iPSCs.50 Vinblastine is another useful small molecule for
cell cycle synchronization in the G2/M phases through
binding to tubulins and blocking microtubule dynamics.95
It is elucidated that Vinblastine increases HDR rate by 6- to
10-fold in HeLa, U-2OS, and HT-1080 cell lines. Likewise,
Indirubins by inhibition of several cyclin-dependent
kinases, leads to cell-cycle prevention in G1/S or G2/M
in different cell models.96 Rahman et al reported that by
utilizing meganuclease I-SceI and ZFNs together with
indirubin-3′-monoxime, the HDR rate increased by 2- to
5-fold in Hela, U-2OS, and HT-1080 cell lines. Incredibly,
indirubin-3′-monoxime results in an enhancement in
HDR by 10-fold in primary umbilical cord–derived
mesenchymal stromal cells (UC-MSCs). Finally, it was
concluded that indirubin-3′-monoxime is a promising
small molecule for enhancing adeno-associated virus/
ZFN-mediated gene editing especially in UC-MSCs for
clinical approaches.97
The effective strategy of modified CRISPR-Cas Systems
for boosting HDR activity
HDR pathway leads to the precise insertion of the donor
template at the DSB site in the presence of a homologous
donor strand. Induction of the HDR pathway for repairing
DSBs which is introduced by CRISPR-Cas9 is a suitable
approach for increasing the accuracy of knocking in
approaches. This procedure provides plenty of technical
capabilities for researchers and industries such as
developing insertions or deletions models, inserting
sequences for epitope tags, generating SNPs, and inserting
whole genes into target site to produce modified organisms.
Although the HDR pathway along with CRISPR-Cas9 is
an easy way to introduce a site-specific rectification, HDR
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activity is very low that has a negative and direct effect on
precision genome engineering functions.98,99 Enhancing
the efficiency of HDR provides fast, easy, and accurate
technologies based on CRISPR-Cas9.44,100 In this regard,
engineering strategies are required for inducing the HDR
pathway for accurate gene modification.
HDR-fusion Cas9
According to previous findings, each of NHEJ and HDR
pathways is dominated in different cell-cycle phases
separately.40,101 In this line, precisely activating Cas9 in S
and G2 phases results in an increased HDR rate. The main
studied fusion motifs include CtIP, Rad52, DN1S, mSA,
and Geminin. These engineered variants usually enhance
knock-in occurrence in both in vivo and in vitro (Fig. 4). It
is reported that by fusing a N-terminal fragment of CtIP,
which is a key protein in HDR initiation, to Cas9 protein, the
CtIP was forced to DSB site that increasing the efficiency of
HDR by 2-folds. Moreover, when comparing the patterns
of indels introduced by wild-type Cas9 and engineered
Cas9, it was speculated that existence of different patterns
could originate from a different balance of DSB repair
pathways.102 According to this observation, recently Tran
et al designed an experiment to establish Cas9 fusion with
other factors which are involved in HDR pathway. They
reported that similar to CtIP, fusing Cas9 to Mre11 and
Rad52 but not Rad51C, could scale up the efficiency of
HDR by 2-fold. Moreover, it was indicated that fusing CtIP
to gRNA through MS2 binding loops resembling Cas9CtIP variant is able to extend the ratio of HDR/NHEJ
approximately by 6-folds (Fig. 4A). Remarkably, when
simultaneously using Cas9-CtIP with MS2-CtIP, the ratio
of HDR/NHEJ boosted up to 14.9-fold.103 However, there
are several limitations in using these chimeric proteins
broadly. For example, Mre11 and CtIP have complex
post-translational regulation and the prediction of protein
interactions is confusing. This phenomenon could not be
profitable because it originates from endogenous cellular
components.104 53BP1 plays a key role in the initiation of
NHEJ. In this line, by inhibiting this protein the efficiency
of HDR would be increased (Fig. 4B). It is indicated that
fusing Cas9 to a truncated piece of p53 named DN1S, a
dominant-negative mutant of 53BP1, could significantly
reduce NHEJ and increase the efficiency of HDR up to
86% especially at DSB sites introduced by CRISPR-Cas9
system in different human cell lines.105 A challenging
limitation for using chimeric Cas9 proteins for increasing
HDR efficiency is their cellular toxicity. It is indicated
that Cas9-DNS1, in reality, increases cellular toxicity by
about 10%. Finally, it should be considered that these
chimeric proteins would not be effective for increasing
HDR ratio because none of these engineered proteins are
involved in regulating long range 5’ to 3’ end resection.106
To address these limitations, Hackley et al fused Cas9
to human Exo1 and reported that this chimeric protein
compared to wild-type, Cas9 is able to increase the rate
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of HDR by 2.5-fold and reduce cellular toxicity about
4-fold (Fig. 4C).107 Furthermore, miCas9 is the recently
developed small-size HDR-fusion variant that increases
HDR capacity. Fusion motif, Brex27 of the engineered
variant interacts with RAD51 and enhances the chance
of RAD51 presence at the target locus. MiCas9 increases
the knock-in rates of large size genes which are mediated
by dsDNA, consistently lessens insertion occurrences and
off-target deletion, and keeps or enhances single-stranded
oligodeoxynucleotide (ssODN)-mediated precise gene
editing rates (Fig. 4D).108 Anti-CRISPR proteins, which
are naturally derived from bacteriophages, are promising
inhibitory proteins for controlling the activity of CRISPRCas systems (Fig. 4E). Recently, Matsumoto et al observed
that during phase S and phase G2 the fused human Cdt1
is degraded where HDR is dominant. When AcrIIA4, the
natural anti-CRISPR protein, was fused to the N-terminus
region of Cdt1, engineered CRISPR-Cas system was
activated at the intended phases, S/G2, and DNA repair
was boosted through HDR.109
Modified sgRNA, Cas9 and/or donor template
For simplifying CRISPR approaches, enhancing the
efficiency of HDR seems laborious. Another helpful
application is employing the assembly of ssDNA
template, sgRNA, and Cas9 along with donor DNA
at the targeted site to a homologous sequence. These
strategies are implemented to increase the ratio of HDR
through bringing donor template close to the introduced
DSB site by CRISPR-Cas9 system. Several reports have
corroborated the simplicity of increasing the HDR
efficiency by advancing the assembly of these components
individually or in a complex.
In agrobacteria, Vir proteins are able to transfer
T-DNA construct into plant cells. VirD2 relaxase is a
component of Vir proteins that covalently binds to the
5’-site of single-stranded T-DNA and by using its nuclear
localization signal, directs attached T-DNA into nucleus
and integrates it in the plant genome. When VirD2 was
fused to Cas9, this chimeric protein was able to recruit
repair template in close proximity to the introduced DSB
by Cas9 and increased HDR rate up to 6-fold more than
repair with Cas9 alone (Fig. 5A). This finding opens up
novel promising opportunities for precise plant genome
editing.110 Several attempts have been taken to recruit
donor oligonucleotides to introduce DSB by Cas9. It is
indicated that donor template could be fused into gRNA
and by using this strategy HDR efficiency was increased
three times.56 Several studies also used the advantage
of biotin-streptavidin interaction for directing donor
template close proximity to Cas9- mediated DSB.111,112
Moreover, the high-affinity biotin-streptavidin interaction
was also used for increasing HDR rate at DSB induced
by CRISPR-Cas9 ribonucleoproteins (RNPs). RNPs have
shorter half-life compared to their plasmid counterparts,
so by using these components the off-target effects would
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Fig. 4 Accumulation of fusion Cas9 to improve the efficiency of the HDR pathway. Generally, knock-in events are less frequent than template-free
indels. (A) Accumulating CtIP via MS2 and association with special sgRNA loops of Cas9 increased knock-in ratio significantly. (B) Fusing Cas9 to DN1S, a
truncated piece of p53 reduces NHEJ and increases the efficiency of HDR. (C) Fusing Cas9 to human Exo1 by inhibiting NHEJ increases the rate of HDR. (D)
To improve the HDR capacity of Cas9, the miCas9 was created by adding thirty-six amino acids to spCas9. Adding Brex27 to miCas9 results in enrichment
of edited region. (E) Activating specific Cas9 system by Anti-CRISPR AcrIIA4 by binding to Cas9-sgRNA acts as an inhibitor for SpyCas9 in G1 phase. In S/
G2/M phases, degradation of Cdt1 (S phase degradation domain) leads to AcrIIA4 degradation and consequently, activates the SpyCas9-sgRNA complex.
Figure was created with BiorRender (https://biorender.com).

be reduced significantly. Recently, it is elucidated that by
combining two cells homologous recombination CRISPR
genome editing with a modified biotin–streptavidin
approach, in a site-specific manner, the knock-in
efficiency of any large fragment could increase up to
95% compared to standard methods in mouse embryos.
Although the function of sgRNA may be interrupted by
linking an aptamer, engineered Cas9 could be recruited
to the biotinylated DNA template. Ma et al fused avidin
to Cas9 in mouse embryos for enhancing the efficiency
of accurate knock-in from 0 to 15-22%. On the other
hand, it was indicated that when wild-type Cas9 is used
all mutations contained indels, generated through NHEJ
(Fig. 5B).111 Furthermore, Gu et al reported the use of mSA
fused to Cas9 for localizing donor DNAs to target sites.
Fusing mSA, because of its monomer structure, to Cas9
demonstrates a biotin-binding domain to recruit repair
templates without accumulating the nuclease (Fig. 5C). By
incorporating reporter genes at 20 different loci in various
cell types, this design was evaluated.113 Several studies
were developed that consistent with other observations
have revealed the crucial role of donor localization to
increase HDR pathway.114-116
Another strategy for directing donor template to
close proximity of Cas9-mediated DSB is to bind donor
template to Cas9 through covalent linkage. In this line,
covalent tethering was reported between RNP complex
form of CRISPR-Cas9 and ssODN via a fusion of
porcine circovirus 2 (PCV) target sequence with HUH
endonuclease. The need to alter donor ssDNA or the
sgRNA is resolved via HUH-tagged recombinant protein
(Fig. 5D). It is estimated that this strategy augmented

HDR efficiency up to 30-fold.116 In addition, Savic et al
reported that donor template can physically link to Cas9
enzyme through a SNAP-tag (Fig. 5E). They indicated
that O6-benzylguanine (BG)-labeled DNA oligos are able
to covalently bind to Cas9-SNAP chimeric proteins and
the efficiency of HDR increased up to 24-fold.115 There
are several limitations for these introduced methods, such
as i) there are technical and commercial difficulties for
obtaining terminally modified long ssOND; and ii) the
expression level of Cas9 or its delivery efficiency might be
changed by fusing a functional domain or linker and also
maybe a susceptible chimeric protein to protease cleavage.
In order to overcome these limitations, recently a novel
innovative strategy known as genetic code–expansion
technology was developed. This technology is established
by using chemically modified Cas9 mutant including an
azide-containing noncanonical amino acid which is able
to recruit modified or unmodified repair template to the
DSB site (Fig. 5F). Such modifications enable conjugation
of alkyne-azide cycloaddition by dibenzylcyclooctyne
(DBCO)-DNA adaptor or dibenzylcyclooctyne modified
donor ssODN, which in turn facilitates recruitment of
the repair template to the cleavage complex for the HDR
pathway. A universal platform is developed by these
Cas9 conjugates for using unmodified ssODNs which are
commercially available at high purity and a low cost to the
RNP complex by base pairing. This strategy increased the
HDR efficiency up to 10-fold in both mouse zygotes and
human cell culture.117
As mentioned about the advantage of biotinstreptavidin interaction, this approach was only successful
for knocking-in large fragments into a limited number of
BioImpacts, 2022, 12(4), 371-391
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Fig. 5 Variation methods for tethering the ssODN donor template to modified Cas9 for enhancing gene editing efficiency. Modified Cas9 along with
sgRNA were joined to ssODN donor template to enhance the rate of precise repair via the targeted HDR pathway (A-F). Figure was created with BiorRender
(https://biorender.com).

targeted loci. Two-cell stage has an exceptional long G2
phase in embryos. In addition, the chromatin state in this
extended phase is open and provides a golden opportunity
for editing enzymes and repair template to easily reach
targeted sites. Recently, S1mplex, a modular RNA aptamerstreptavidin strategy (Fig. 6), was developed for delivering
RNP form of purified CRISPR-Cas9 system together with
an engineered sgRNA containing a streptavidin-binding
aptamer into target cell for in vitro or ex vivo genome
editing. It is reported that this system increased precise
editing up to 18-fold and augmented pool cells including
multiplexed precise edits by 42-fold.112
Furthermore, new genetic information can help to
increase HDR efficiency by utilizing timed delivery
of CRISPR-RNP complexes along with various drugs
which are arresting the cell cycle.118 In addition, recently
inhibiting main factors in NHEJ and stimulating proteins
participating in HDR by using small molecules are highly
regarded.40
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Small molecules impact on improving CRISPR-Casmediated gene or transcript editing
Over the past decade, several studies have been done on
the effect of small molecules on improving the genome
editing systems. Pruett-Miller et al used small molecules to
enhance the rate of gene targeting by ZFN and reduced its
toxicity. Indeed, they could increase transiently expression
level of the modified ZFNs, by adding a manipulated
destabilizing FKBP12 domain to the N-terminus, fusing
a ubiquitin moiety to the N-terminus, linking a modified
destabilizing FKBP12 domain to the N-terminus, adding
MG132 proteasome inhibitor and Shield1 synthetic
ligand.119 Intuition of the CRISPR-cas9 system has
revolutionized genomic editing approaches. Using small
molecules for regulating Cas9 activity to improve the
efficiency of this system have been recently investigated in
both direct and indirect approaches. In the direct approach,
Davis et al generated a Cas9 endonuclease with impaired
cleavage activity by incorporating a 4- hydroxytamoxifen

Small molecules and modified CRISPR-Cas9 tools for accurate gene editing

Fig. 6 Engineered sgRNA which is harboring a streptavidin aptamer that contains streptavidin-binding aptamer was joined to a biotinylated
ssODNA donor providing an efficient method of recruiting biotinylated DNA. Figure was created with BioRender (https://biorender.com).

(4-HT)- responsive intein sequence at specific positions.
In the presence of 4-HT, this small molecule binds to
intein, enforces conformational changes, provokes protein
splicing, and restores the DNA cleavage activity of inactive
Cas9. This approach showed that conditionally activated
Cas9 corrects target genomic sites with higher specificity
(up to 25-fold) than wild-type Cas9 in human cells.120 The
indirect approach has relied on the regulation of Cas9
activity by using small molecules that target endogenous
cellular processes.91 By analyzing 4000 small molecules
with known function, Brefeldin A, a small molecule
inhibiting protein transportation between endoplasmic
reticulum to Golgi apparatus and L755507, an β3adrenergic receptor agonist, increased targeted reporter
gene integration by 2-fold and 3-fold, respectively.7 It is
indicated that SCR7 is able to enhance the proficiency of
the genome editing which is performed by CRISPR-Cas9
technology.77 Maruyama et al demonstrated that by using
CRISPR-Cas9 technology, SCR7 is able to increase the
HDR efficiency approximately to 19-fold in mammalian
cells and mouse embryos. Indeed, this increased efficiency
has a positive dual function on the HDR pathway and
CRISPR-Cas9 system.8 Moreover, the small molecules
involved in the stimulation of the HDR pathway, such
as RS-1, are able to increase the CRISPR-Cas9 efficiency.
Pinder et al showed that RS-1 increases the performance
of both Cas9 and HDR up to 3-fold.45 Moreover, the
combination of small molecules known as "CRISPY mix",
such as NU7026, MLN4924, inhibiting neddylation of
CtIP, Trichostatin A, and NSC15520, in collaboration
with Cas9 nickase, enhanced the efficiency of knockin experiments.46 Besides all successful achievements in
increasing HDR efficiency through stimulation of HDR
or inhibition of NHEJ, it should be considered that these
strategies are harmful to genome integrity.121 On one hand,
inhibition of NHEJ would increase premature aging and
the incidence of cancers. On the other hand, stimulation
of RAD51 would lead to an augmentation in spontaneous
recombination especially across widespread repetitive
sequences which in turn, could result in loss of key genetic
information.122,123 In this line, discovering small molecules
with minimal off-target effects on global genome
stability sounds extremely crucial. Recently, Zhang et al
established a novel and easy-to-score screening system

by doing a mechanistic study and analyzing 722 natural
small molecules which are commonly used in traditional
Chinese medicine. It is elucidated that farrerol, isolated
from Rhododendron dauricum, with anti-inflammatory
and anti-bacterial properties, scaled up homologous
recombination without any effect on NHEJ. Furthermore,
this natural small molecule enhanced CRISPR-Cas9mediated genome editing in different in vitro and in
vivo models.124 Precise control over exposure time and
expression level of CRISPR-Cas9 system during gene
editing approaches is extremely important for enhancing
its application. To address this serious challenge, Wu et
al generated a chimeric endonuclease by fusing small
molecule-assisted shut-off (SMASh) to Cas9 protein. It
was well-demonstrated that in the presence of hepatitis
C virus (HCV) protease inhibitor asunaprevir (ASV), a
clinically approved small molecule for HCV, this chimeric
endonuclease degraded but upon ASV removal, this
phenomenon reversed. Generating chimeric endonuclease
such as Cas9-SMASH fusion could increase the accuracy
and versatility of genome editing approach based on
CRISPR-Cas9 technology.125 Although CRISPR-Cas9
technology has presented high efficiency in various in vitro
and in vivo models, knock-in efficiency by this technology
has not been successful in hESC. Cas12a (also known as
Cpf1) is a CRISPR effector which is categorized in class
II- type V. CRISPR-Cas12a has shown promising potential
for expanding genome editing toolbox. One special feature
of this system is introducing a staggered DSB in targeted
regions which seems to have increased the HDR rate.126
A high-throughput chemical screening for identifying the
candidate small molecules elucidated that AZD-7762 and
VE-822 are able to improve CRISPR-Cas12a -mediated
precise genome engineering.54 Furthermore, the design
of a new paradigm for stimulation of the structure of Cas
protein and/or small molecules interaction with CasDNA seems a logical approach for the enhancement of the
efficiency of the CRISPR-Cas mediated gene editing. In
this line, Li et al provided a new paradigm for modulating
the efficiency of CRISPR-Cas12a-mediated gene editing by
small molecules. According to their results, a rational small
molecule, quinazoline-2,4(1H,3H)-dione, is able to work
like a molecular glue between Acidaminococcus Cas12a
(AsCas12a) and crRNA and stabilize endonuclease-crRNA
BioImpacts, 2022, 12(4), 371-391
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complex which in turn, would improve the efficiency of
gene editing which is mediated by AsCas12a mammalian
cells.127 Manipulation of genetic information flow at
the RNA level provides the opportunity to change the
expression level of genes without long-term modification
to the host genome. Cas13 proteins are CRISPR effectors
with RNA targeting activity and are classified into class
II- type VI. CRISPR-Cas13 has shown promising results
in RNA targeting strategies and RNA-based diagnostic
tests.128 The large size (~100-130 kDa) and bacterial origin
restrain the applications of CRISPR-Cas13 technology in
both research and therapeutic developments. Recently,
a novel CRISPR-Cas-inspired RNA targeting system
(CIRTS) was generated to overcome these limitations.
CIRTS is an engineered RNP that is able to recruit protein
cargo site-selectively to target the transcript through using
Watson-Crick-Franklin base-pair interactions with a
gRNA.129 In order to temporally control CIRTS dynamics,
a small molecule-inducible RNA-targeting platform
was established based on this effector by coupling
heterodimerization domains of the abscisic acid small
molecule system with CIRTS. This system provides an
opportunity to easily target any desired transcript under a
small molecule inducible-CIRTS platform.130

CRISPR-Cas applications in in vivo preclinical and
clinical models
Currently, most of clinical applications which are
mediated by CRISPR-Cas technology for monogenic
disorders are ex vivo approaches. During last years,
several in vivo gene editing studies have been represented
that target both HDR and NHEJ pathways. Since the
efficiency of in vivo editing is lower compared to in vitro,
a screening approach for detecting the modified cells
through accurate editing boosts the feasibility of HDR
approach in clinical models.131 Although CRISPR-Cas9
has been used in ex vivo clinical trials related to human
immunodeficiency virus-1 (HIV) infection, cancers,
b-thalassemia (ClinicalTrials.gov: NCT03655678), and
sickle cell disease(ClinicalTrials.gov: NCT03745287),
mentioned strategies such as synchronization, modified
CRISPR-Cas Systems, and small molecules in the clinical
models could be promising in future. Some of the recent
applications based on HDR gene editing in preclinical
and clinical models are presented in Table 3. Hereon,
we emphasize several HDR-based accurate in vivo gene
editing experiments utilizing CRISPR-Cas that can be
potentially applied to human in future.

Table 3. List of the recent therapeutic gene editing studies based on HDR in preclinical models

Human disease

Organ

Editing strategy

Delivery system

Gene editing tool

Ref.

Hemophilia A and B

Mouse liver

HDR-dependent gene insertion

Systemic injection of AAV8

ZFN

132

Hemophilia A and B

Mouse liver

HDR-based corrective gene editing Systemic injection of AAV8

ZFN

133

Hemophilia B

Mouse liver

Injection of AAV8

CRISPR-Cas9

134

Hemophilia B

Mouse liver

Intravenous injection of AAV8

CRISPR-Cas9

135

Hemophilia B

Mouse liver

CRISPR-Cas9

136

Hunter's syndrome

Mouse liver

ZFN

137

CRISPR-Cas9

138

CRISPR-Cas9

139

CRISPR-Cas9

140

CRISPR-Cas9

141

CRISPR-Cas9

142

Mouse liver

HTI

Rat liver

HTI
AATD

Mouse liver
Mouse
muscle
Mouse
muscle

DMD
DMD

HDR-based point mutation
correction
HDR-mediated insert into mFIX
into murine ROSA26 safe harbor
HDR-based point mutation
correction in F9 locus
HDR-mediated integration into
albumin locus
HDR-based point mutation
correction
HDR-based point mutation
correction
HDR-based point mutation
correction
HDR-mediated dystrophin gene
correction
HDR-based point mutation
correction

Intravenous injection of adenovirus
Systemic injection of AAV8
Intravenous injection of AAV2/8 and LNP
Intravenous injection of adenovirus
Intravenous and intraperitoneal injection
of AAV
Intramuscular and retro-orbital injection
of dual AAV6
Intramuscular injection of Gold
nanoparticle Cas9 RNP and donor DNA

Retinitis pigmentosa

Mouse Eye

HDR-based point mutation
correction

Subretinal and electroporation of RecAMS2 Plasmid and ssDNA donor

CRISPR-Cas9/ RecA

143

OTC deficiency

Mouse liver

HDR-based point mutation
correction

Intravenous injection of AAV8

CRISPR-Cas9

144

OTC deficiency

Mouse liver

HDR- mediated insert codon
optimized human OTC into intron
4 of mouse OTC locus

Intravenous injection of AAV8

CRISPR-Cas9

145

MPS type I

Multiorgan

HDR- mediated insert Idua into
murine ROSA26 safe harbor

Intravenous injection of cationic
liposomes

CRISPR-Cas9

146

AAV, adeno-associated virus; mFIX, factor IX; HTI, hereditary tyrosinemia; LNP, lipid nanoparticle; AATD, alpha-1 antitrypsin deficiency; DMD, Duchenne
muscular dystrophy; OTC, ornithine transcarbamylase; MPS, mucopolysaccharidosis.
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Review Highlights
What is the current knowledge?
√ HDR is attractive for its high fidelity; the choice of repair
pathway is biased in a biological context.
√ Mammalian cells preferentially employ NHEJ over and
HDR is restricted.
What is new here?
√ Facilitating the development of a modified CRISPR-Cas9
system to achieve more precise gene editing.
√ Suggesting the remarkable advantage of small molecules for
establishing drug inducible genome editing platforms.
√ Drug inducible genome editing platform would help
to control editing approaches dose- and exposure timedependently.

Conclusion
The stimulation of HDR pathway can increase the
accuracy of CRISPR-Cas-mediated engineering systems.
Generating chimeric programmable endonucleases
provides this opportunity to direct DNA template close
proximity of CRISPR-Cas-mediated DSB. However, it
should be considered that by fusing a functional domain
or linker, the expression level of Cas9 or its delivery
efficiency might be changed and also the generated
fusion protein may be prone to protease cleavage. Small
molecules and their derivatives are able to proficiently
block or activate certain DNA repair pathways. Most small
molecules increase precise genome editing through HDR.
The results of most studies suggest that for increasing
HDR-driven knock-in events, blockade of NHEJ is more
efficient than improving HDR. Furthermore, the targeting
upstream protein in NHEJ provides a greater potential for
increasing the HDR-mediated gene insertion. Nonetheless,
small molecules have unequal and even diverse influences
on the efficiency of precise genome editing in various
cell models. Hence, it is necessary to survey the efficacy
of this approach in certain cells, different DNA loci, and
in vivo studies. In summary, inhibitors of DNA-PK and
ligase complex enhance the efficiency of precise genome
editing efficiency in various cell types. There is serious
consideration about genome integrity by inhibiting NHEJ
or stimulating HDR components. In this line, discovering
safe natural products such as farrerol, which is able to
increase HDR with no effect on NHEJ, brings up a novel
perspective for increasing the efficiency of genome editing
approach. Ultimately, high throughput screening of small
molecule libraries could result in more discoveries of
promising chemicals that improve HDR efficiency and
CRISPR-Cas9 systems. Another remarkable advantage of
small molecules is their usefulness for establishing druginducible genome editing platforms. This finding would
help researchers temporally control the dose and exposure
time of genome or transcriptome editing tools.

Acknowledgments
The authors wish to express their gratitude for financial support from
Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Funding sources
Shahid Beheshti University of Medical Sciences, Tehran, Iran (grant No.
11451).
Ethical statement
Not applicable.
Competing interests
Authors declare they do not have any conflict of interests.
Authors’ contribution
FSh: conceptualization and draft preparation, writing and reviewing.
HD: study consultation, writing and reviewing. OM: conceptualization
and draft preparation. SM, HV, MS: study consultation and validation.
AR: supervision, writing and reviewing, and project administration.
References
1.
Karagyaur MN, Rubtsov YP, Vasiliev PA, Tkachuk VA. Practical
Recommendations for Improving Efficiency and Accuracy of the
CRISPR/Cas9 Genome Editing System. Biochem (Mosc) 2018; 83:
629-42. https://doi.org/10.1134/S0006297918060020
2.
Bayat H, Omidi M, Rajabibazl M, Sabri S, Rahimpour A. The
CRISPR Growth Spurt: from Bench to Clinic on Versatile Small
RNAs. J Microbiol Biotechnol 2017; 27: 207-18. https://doi.
org/10.4014/jmb.1607.07005
3.
Golchin A, Shams F, Karami F. Advancing Mesenchymal Stem Cell
Therapy with CRISPR/Cas9 for Clinical Trial Studies. Adv Exp Med
Biol 2020; 1247: 89-100. https://doi.org/10.1007/5584_2019_459
4.
Bayat H, Naderi F, Khan AH, Memarnejadian A, Rahimpour A.
The Impact of CRISPR-Cas System on Antiviral Therapy. Adv
Pharm Bull 2018; 8: 591-7. https://doi.org/10.15171/apb.2018.067
5.
Salmaninejad A, Jafari Abarghan Y, Bozorg Qomi S, Bayat H,
Yousefi M, Azhdari S, et al. Common therapeutic advances for
Duchenne muscular dystrophy (DMD). Int J Neurosci 2021; 131:
370-89. https://doi.org/10.1080/00207454.2020.1740218
6.
Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak
J, Bijak M. Various Aspects of a Gene Editing System—CRISPR–
Cas9. Int J Mol Sci 2020; 21:9604. https://doi.org/10.3390/
ijms21249604
7.
Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y, et al. Small molecules
enhance CRISPR genome editing in pluripotent stem cells. Cell Stem
Cell 2015; 16: 142-7. https://doi.org/10.1016/j.stem.2015.01.003
8.
Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR,
Ploegh HL. Increasing the efficiency of precise genome editing
with CRISPR-Cas9 by inhibition of nonhomologous end joining.
Nat Biotechnol 2015; 33: 538-42. https://doi.org/10.1038/nbt.3190
9.
Kakarougkas A, Jeggo PA. DNA DSB repair pathway choice: an
orchestrated handover mechanism. Br J Radiol 2014; 87: 20130685.
https://doi.org/10.1259/bjr.20130685
10. Chiruvella KK, Liang Z, Wilson TE. Repair of double-strand breaks
by end joining. Cold Spring Harb Perspect Biol 2013; 5: a012757.
https://doi.org/10.1101/cshperspect.a012757
11. Bae S, Kweon J, Kim HS, Kim JS. Microhomology-based choice of
Cas9 nuclease target sites. Nat Methods 2014; 11: 705-6. https://doi.
org/10.1038/nmeth.3015
12. Callen E, Faryabi RB, Luckey M, Hao B, Daniel JA, Yang W, et al.
The DNA damage- and transcription-associated protein paxip1
controls thymocyte development and emigration. Immunity 2012;
37: 971-85. https://doi.org/10.1016/j.immuni.2012.10.007
13. Chapman JR, Barral P, Vannier JB, Borel V, Steger M, Tomas-Loba
A, et al. RIF1 is essential for 53BP1-dependent nonhomologous
end joining and suppression of DNA double-strand break
resection. Mol Cell 2013; 49: 858-71. https://doi.org/10.1016/j.
molcel.2013.01.002
14. Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, et
BioImpacts, 2022, 12(4), 371-391

387

Shams et al

15.

16.

17.

18.

19.

20.

21.
22.
23.
24.
25.

26.

27.

28.

29.
30.
31.
32.

388

al. SHLD2/FAM35A co-operates with REV7 to coordinate DNA
double-strand break repair pathway choice. EMBO J 2018; 37:
e100158. https://doi.org/10.15252/embj.2018100158
Ghezraoui H, Oliveira C, Becker JR, Bilham K, Moralli D, Anzilotti
C, et al. 53BP1 cooperation with the REV7-shieldin complex
underpins DNA structure-specific NHEJ. Nature 2018; 560: 122-7.
https://doi.org/10.1038/s41586-018-0362-1
Waters CA, Strande NT, Wyatt DW, Pryor JM, Ramsden DA.
Nonhomologous end joining: a good solution for bad ends.
DNA Repair (Amst) 2014; 17: 39-51. https://doi.org/10.1016/j.
dnarep.2014.02.008
Pawelczak KS, Turchi JJ. A mechanism for DNA-PK activation
requiring unique contributions from each strand of a DNA terminus
and implications for microhomology-mediated nonhomologous
DNA end joining. Nucleic Acids Res 2008; 36: 4022-31. https://doi.
org/10.1093/nar/gkn344
Radhakrishnan SK, Lees-Miller SP. DNA requirements for
interaction of the C-terminal region of Ku80 with the DNAdependent protein kinase catalytic subunit (DNA-PKcs).
DNA Repair (Amst) 2017; 57: 17-28. https://doi.org/10.1016/j.
dnarep.2017.06.001
Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Nonhomologous DNA end joining and alternative pathways to doublestrand break repair. Nat Rev Mol Cell Biol 2017; 18: 495-506.
https://doi.org/10.1038/nrm.2017.48
Daley JM, Laan RL, Suresh A, Wilson TE. DNA joint dependence
of pol X family polymerase action in nonhomologous end joining.
J Biol Chem 2005; 280: 29030-7. https://doi.org/10.1074/jbc.
M505277200
Paull TT. Saving the ends for last: the role of pol mu in DNA
end joining. Mol Cell 2005; 19: 294-6. https://doi.org/10.1016/j.
molcel.2005.07.008
Andres SN, Vergnes A, Ristic D, Wyman C, Modesti M, Junop M.
A human XRCC4-XLF complex bridges DNA. Nucleic Acids Res
2012; 40: 1868-78. https://doi.org/10.1093/nar/gks022
McVey M, Lee SE. MMEJ repair of double-strand breaks (director's
cut): deleted sequences and alternative endings. Trends Genet 2008;
24: 529-38. https://doi.org/10.1016/j.tig.2008.08.007
Sinha S, Villarreal D, Shim EY, Lee SE. Risky business:
Microhomology-mediated end joining. Mutat Res 2016; 788: 1724. https://doi.org/10.1016/j.mrfmmm.2015.12.005
Truong LN, Li Y, Shi LZ, Hwang PY, He J, Wang H, et al.
Microhomology-mediated End Joining and Homologous
Recombination share the initial end resection step to repair DNA
double-strand breaks in mammalian cells. Proc Natl Acad Sci U S A
2013; 110: 7720-5. https://doi.org/10.1073/pnas.1213431110
Rahal EA, Henricksen LA, Li Y, Williams RS, Tainer JA, Dixon
K. ATM regulates Mre11-dependent DNA end-degradation and
microhomology-mediated end joining. Cell Cycle 2010; 9: 2866-77.
https://doi.org/10.4161/cc.9.14.12363
Ahmad A, Robinson AR, Duensing A, van Drunen E, Beverloo
HB, Weisberg DB, et al. ERCC1-XPF endonuclease facilitates DNA
double-strand break repair. Mol Cell Biol 2008; 28: 5082-92. https://
doi.org/10.1128/mcb.00293-08
Drane P, Brault ME, Cui G, Meghani K, Chaubey S, Detappe A,
et al. TIRR regulates 53BP1 by masking its histone methyl-lysine
binding function. Nature 2017; 543: 211-6. https://doi.org/10.1038/
nature21358
Anuchina AA, Lavrov AV, Smirnikhina SA. TIRR: a potential front
runner in HDR race-hypotheses and perspectives. Mol Biol Rep
2020; 47: 2371-9. https://doi.org/10.1007/s11033-020-05285-x
Symington LS. End resection at double-strand breaks: mechanism
and regulation. Cold Spring Harb Perspect Biol 2014; 6: a016436.
https://doi.org/10.1101/cshperspect.a016436
Paull TT. Mechanisms of ATM Activation. Annu Rev
Biochem 2015; 84: 711-38. https://doi.org/10.1146/annurevbiochem-060614-034335
Kijas AW, Lim YC, Bolderson E, Cerosaletti K, Gatei M, Jakob B, et
al. ATM-dependent phosphorylation of MRE11 controls extent of
resection during homology directed repair by signalling through
BioImpacts, 2022, 12(4), 371-391

33.

34.

35.

36.
37.
38.

39.

40.
41.
42.
43.
44.

45.

46.

47.

48.

49.

50.

Exonuclease 1. Nucleic Acids Res 2015; 43: 8352-67. https://doi.
org/10.1093/nar/gkv754
Nimonkar AV, Genschel J, Kinoshita E, Polaczek P, Campbell JL,
Wyman C, et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPAMRN constitute two DNA end resection machineries for human
DNA break repair. Genes Dev 2011; 25: 350-62. https://doi.
org/10.1101/gad.2003811
Kakarougkas A, Ismail A, Katsuki Y, Freire R, Shibata A, Jeggo PA.
Co-operation of BRCA1 and POH1 relieves the barriers posed by
53BP1 and RAP80 to resection. Nucleic Acids Res 2013; 41: 10298311. https://doi.org/10.1093/nar/gkt802
Butler LR, Densham RM, Jia J, Garvin AJ, Stone HR, Shah V, et
al. The proteasomal de-ubiquitinating enzyme POH1 promotes the
double-strand DNA break response. EMBO J 2012; 31: 3918-34.
https://doi.org/10.1038/emboj.2012.232
Symington LS, Gautier J. Double-strand break end resection and
repair pathway choice. Annu Rev Genet 2011; 45: 247-71. https://
doi.org/10.1146/annurev-genet-110410-132435
Kim KP, Mirkin EV. So similar yet so different: The two ends of
a double strand break. Mutat Res 2018; 809: 70-80. https://doi.
org/10.1016/j.mrfmmm.2017.06.007
Bell JC, Kowalczykowski SC. Mechanics and SingleMolecule Interrogation of DNA Recombination. Annu Rev
Biochem 2016; 85: 193-226. https://doi.org/10.1146/annurevbiochem-060614-034352
Pellegrini L, David SY, Lo T, Anand S, Lee M, Blundell TL, et
al. Insights into DNA recombination from the structure of a
RAD51–BRCA2 complex. Nature 2002; 420: 287-93. https://doi.
org/10.1038/nature01230
Smirnikhina SA, Anuchina AA, Lavrov AV. Ways of improving
precise knock-in by genome-editing technologies. Hum Genet
2019; 138: 1-19. https://doi.org/10.1007/s00439-018-1953-5
Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices
and consequences at the double-strand break. Trends Cell Biol
2016; 26: 52-64. https://doi.org/10.1016/j.tcb.2015.07.009
Liu M, Rehman S, Tang X, Gu K, Fan Q, Chen D, et al.
Methodologies for Improving HDR Efficiency. Front Genet 2018;
9: 691. https://doi.org/10.3389/fgene.2018.00691
Sung P. Function of yeast Rad52 protein as a mediator between
replication protein A and the Rad51 recombinase. J Biol Chem
1997; 272: 28194-7. https://doi.org/10.1074/jbc.272.45.28194
Pawelczak KS, Gavande NS, VanderVere-Carozza PS, Turchi JJ.
Modulating DNA Repair Pathways to Improve Precision Genome
Engineering. ACS Chem Biol 2018; 13: 389-96. https://doi.
org/10.1021/acschembio.7b00777
Pinder J, Salsman J, Dellaire G. Nuclear domain 'knock-in' screen
for the evaluation and identification of small molecule enhancers
of CRISPR-based genome editing. Nucleic Acids Res 2015; 43:
9379-92. https://doi.org/10.1093/nar/gkv993
Riesenberg S, Maricic T. Targeting repair pathways with small
molecules increases precise genome editing in pluripotent stem
cells. Nat Commun 2018; 9: 2164. https://doi.org/10.1038/s41467018-04609-7
Suzuki K, Tsunekawa Y, Hernandez-Benitez R, Wu J, Zhu J, Kim
EJ, et al. In vivo genome editing via CRISPR/Cas9 mediated
homology-independent targeted integration. Nature 2016; 540:
144-9. https://doi.org/10.1038/nature20565
Kostyushev D, Kostyusheva A, Brezgin S, Zarifyan D, Utkina A,
Goptar I, et al. Suppressing the NHEJ pathway by DNA-PKcs
inhibitor NU7026 prevents degradation of HBV cccDNA cleaved
by CRISPR/Cas9. Sci Rep 2019; 9: 1847. https://doi.org/10.1038/
s41598-019-38526-6
Jayavaradhan R, Pillis DM, Malik P. A Versatile Tool for the
Quantification of CRISPR/Cas9-Induced Genome Editing
Events in Human Hematopoietic Cell Lines and Hematopoietic
Stem/Progenitor Cells. J Mol Biol 2019; 431: 102-10. https://doi.
org/10.1016/j.jmb.2018.05.005
Zhang JP, Li XL, Li GH, Chen W, Arakaki C, Botimer GD, et
al. Efficient precise knockin with a double cut HDR donor after
CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome

Small molecules and modified CRISPR-Cas9 tools for accurate gene editing
51.

52.

53.

54.

55.

56.

57.

58.

59.
60.

61.

62.

63.

64.

65.

66.
67.

68.

Biol 2017; 18: 35. https://doi.org/10.1186/s13059-017-1164-8
Robert F, Barbeau M, Ethier S, Dostie J, Pelletier J. Pharmacological
inhibition of DNA-PK stimulates Cas9-mediated genome editing.
Genome Med 2015; 7: 93. https://doi.org/10.1186/s13073-0150215-6
Riesenberg S, Chintalapati M, Macak D, Kanis P, Maricic T, Paabo
S. Simultaneous precise editing of multiple genes in human cells.
Nucleic Acids Res 2019; 47: e116. https://doi.org/10.1093/nar/
gkz669
Weterings E, Gallegos AC, Dominick LN, Cooke LS, Bartels TN,
Vagner J, et al. A novel small molecule inhibitor of the DNA repair
protein Ku70/80. DNA Repair (Amst) 2016; 43: 98-106. https://doi.
org/10.1016/j.dnarep.2016.03.014
Ma X, Chen X, Jin Y, Ge W, Wang W, Kong L, et al. Small molecules
promote CRISPR-Cpf1-mediated genome editing in human
pluripotent stem cells. Nat Commun 2018; 9: 1303. https://doi.
org/10.1038/s41467-018-03760-5
Hu Z, Shi Z, Guo X, Jiang B, Wang G, Luo D, et al. Ligase IV
inhibitor SCR7 enhances gene editing directed by CRISPR-Cas9
and ssODN in human cancer cells. Cell Biosci 2018; 8: 12. https://
doi.org/10.1186/s13578-018-0200-z
Lee JS, Grav LM, Pedersen LE, Lee GM, Kildegaard HF. Accelerated
homology-directed targeted integration of transgenes in Chinese
hamster ovary cells via CRISPR/Cas9 and fluorescent enrichment.
Biotechnol Bioeng 2016; 113: 2518-23. https://doi.org/10.1002/
bit.26002
Yao X, Zhang M, Wang X, Ying W, Hu X, Dai P, et al. TildCRISPR Allows for Efficient and Precise Gene Knockin in Mouse
and Human Cells. Dev Cell 2018; 45: 526-36 e5. https://doi.
org/10.1016/j.devcel.2018.04.021
Gutschner T, Haemmerle M, Genovese G, Draetta GF, Chin
L. Post-translational Regulation of Cas9 during G1 Enhances
Homology-Directed Repair. Cell Rep 2016; 14: 1555-66. https://
doi.org/10.1016/j.celrep.2016.01.019
Singh P, Schimenti JC, Bolcun-Filas E. A mouse geneticist's
practical guide to CRISPR applications. Genetics 2015; 199: 1-15.
https://doi.org/10.1534/genetics.114.169771
Li G, Zhang X, Zhong C, Mo J, Quan R, Yang J, et al. Small
molecules enhance CRISPR/Cas9-mediated homology-directed
genome editing in primary cells. Sci Rep 2017; 7: 8943. https://doi.
org/10.1038/s41598-017-09306-x
Zhang Y, Zhang Z, Ge W. An efficient platform for generating
somatic point mutations with germline transmission in the
zebrafish by CRISPR/Cas9-mediated gene editing. J Biol Chem
2018; 293: 6611-22. https://doi.org/10.1074/jbc.RA117.001080
Pan Y, Shen N, Jung-Klawitter S, Betzen C, Hoffmann GF, Hoheisel
JD, et al. CRISPR RNA-guided FokI nucleases repair a PAH variant
in a phenylketonuria model. Sci Rep 2016; 6: 35794. https://doi.
org/10.1038/srep35794
Aksoy YA, Nguyen DT, Chow S, Chung RS, Guillemin GJ, Cole
NJ, et al. Chemical reprogramming enhances homology-directed
genome editing in zebrafish embryos. Commun Biol 2019; 2: 198.
https://doi.org/10.1038/s42003-019-0444-0
Lamas‐Toranzo I, Martínez‐Moro A, Millán‐Blanca G, Sánchez J,
Lonergan P, Bermejo‐Álvarez P. RS‐1 enhances CRISPR‐mediated
targeted knock‐in in bovine embryost. Mol Reprod Dev 2020; 87:
542-549. https://doi.org/10.1002/mrd.23341
Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears
CR, Pawelczak KS, et al. DNA repair targeted therapy: The past
or future of cancer treatment? Pharmacol Ther 2016; 160: 65-83.
https://doi.org/10.1016/j.pharmthera.2016.02.003
Davidson D, Amrein L, Panasci L, Aloyz R. Small Molecules,
Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond. Front
Pharmacol 2013; 4: 5. https://doi.org/10.3389/fphar.2013.00005
Tavecchio M, Munck JM, Cano C, Newell DR, Curtin NJ.
Further characterisation of the cellular activity of the DNA-PK
inhibitor, NU7441, reveals potential cross-talk with homologous
recombination. Cancer Chemother Pharmacol 2012; 69: 155-64.
https://doi.org/10.1007/s00280-011-1662-4
Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C,

69.

70.

71.

72.

73.

74.

75.

76.

77.

78.

79.

80.
81.
82.
83.

84.
85.

et al. Chemosensitization of cancer cells by KU-0060648, a dual
inhibitor of DNA-PK and PI-3K. Mol Cancer Ther 2012; 11: 178998. https://doi.org/10.1158/1535-7163.MCT-11-0535
Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin
V, Pehl U, et al. Pharmacologic Inhibitor of DNA-PK, M3814,
Potentiates Radiotherapy and Regresses Human Tumors in
Mouse Models. Mol Cancer Ther 2020; 19: 1091-101. https://doi.
org/10.1158/1535-7163.MCT-19-0734
Sirrenberg C, Zimmermann A, Grombacher T, Vassilev LT,
Damstrup L, Zenke FT, et al. A novel selective DNA-PK inhibitor,
M3814, as a potential combination partner of Etoposide and
Cisplatin in the therapy of lung cancer. AACR 2017; 77: 4183.
https://doi.org/10.1158/1538-7445.AM2017-4183
Sun Q, Guo Y, Liu X, Czauderna F, Carr MI, Zenke FT, et al.
Therapeutic Implications of p53 Status on Cancer Cell Fate
Following Exposure to Ionizing Radiation and the DNA-PK
Inhibitor M3814. Mol Cancer Res 2019; 17: 2457-68. https://doi.
org/10.1158/1541-7786.MCR-19-0362
Gavande NS, VanderVere-Carozza PS, Pawelczak KS, MendozaMunoz P, Vernon TL, Hanakahi LA, et al. Discovery and
development of novel DNA-PK inhibitors by targeting the unique
Ku-DNA interaction. Nucleic Acids Res 2020; 48: 11536-50. https://
doi.org/10.1093/nar/gkaa934
Freschauf GK, Karimi-Busheri F, Ulaczyk-Lesanko A, Mereniuk
TR, Ahrens A, Koshy JM, et al. Identification of a small molecule
inhibitor of the human DNA repair enzyme polynucleotide
kinase/phosphatase. Cancer Res 2009; 69: 7739-46. https://doi.
org/10.1158/0008-5472.CAN-09-1805
Chen X, Zhong S, Zhu X, Dziegielewska B, Ellenberger T, Wilson
GM, et al. Rational design of human DNA ligase inhibitors that
target cellular DNA replication and repair. Cancer Res 2008; 68:
3169-77. https://doi.org/10.1158/0008-5472.CAN-07-6636
Srivastava M, Nambiar M, Sharma S, Karki SS, Goldsmith G, Hegde
M, et al. An inhibitor of nonhomologous end-joining abrogates
double-strand break repair and impedes cancer progression. Cell
2012; 151: 1474-87. https://doi.org/10.1016/j.cell.2012.11.054
Ma Y, Chen W, Zhang X, Yu L, Dong W, Pan S, et al. Increasing
the efficiency of CRISPR/Cas9-mediated precise genome editing in
rats by inhibiting NHEJ and using Cas9 protein. RNA Biol 2016; 13:
605-12. https://doi.org/10.1080/15476286.2016.1185591
Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, Kühn R.
Increasing the efficiency of homology-directed repair for CRISPRCas9-induced precise gene editing in mammalian cells. Nat
Biotechnol 2015; 33: 543-8. https://doi.org/10.1038/nbt.3198
Yang D, Scavuzzo MA, Chmielowiec J, Sharp R, Bajic A, Borowiak
M. Enrichment of G2/M cell cycle phase in human pluripotent
stem cells enhances HDR-mediated gene repair with customizable
endonucleases. Sci Rep 2016; 6: 21264. https://doi.org/10.1038/
srep21264
Gerlach M, Kraft T, Brenner B, Petersen B, Niemann H, Montag J.
Efficient Knock-in of a Point Mutation in Porcine Fibroblasts Using
the CRISPR/Cas9-GMNN Fusion Gene. Genes (Basel) 2018; 9: 269.
https://doi.org/10.3390/genes9060296
Song J, Yang D, Xu J, Zhu T, Chen YE, Zhang J. RS-1 enhances
CRISPR/Cas9-and TALEN-mediated knock-in efficiency. Nat
Commun 2016; 7:10548. https://doi.org/10.1038/ncomms10548
Greco GE, Matsumoto Y, Brooks RC, Lu Z, Lieber MR, Tomkinson
AE. SCR7 is neither a selective nor a potent inhibitor of human
DNA ligase IV. DNA Repair 2016; 43: 18-23.
Singh AM, Adjan Steffey VV, Yeshi T, Allison DW. Gene Editing in
Human Pluripotent Stem Cells: Choosing the Correct Path. J Stem
Cell Regen Biol 2015; 1.
Shy BR, MacDougall MS, Clarke R, Merrill BJ. Co-incident
insertion enables high efficiency genome engineering in mouse
embryonic stem cells. Nucleic Acids Res 2016; 44: 7997-8010.
https://doi.org/10.1093/nar/gkw685
San Filippo J, Sung P, Klein H. Mechanism of eukaryotic
homologous recombination. Annu Rev Biochem 2008; 77: 229-57.
https://doi.org/10.1146/annurev.biochem.77.061306.125255
Mason JM, Dusad K, Wright WD, Grubb J, Budke B, Heyer WD, et
BioImpacts, 2022, 12(4), 371-391

389

Shams et al
al. RAD54 family translocases counter genotoxic effects of RAD51
in human tumor cells. Nucleic Acids Res 2015; 43: 3180-96. https://
doi.org/10.1093/nar/gkv175
86. Jayathilaka K, Sheridan SD, Bold TD, Bochenska K, Logan HL,
Weichselbaum RR, et al. A chemical compound that stimulates
the human homologous recombination protein RAD51. Proc
Natl Acad Sci U S A 2008; 105: 15848-53. https://doi.org/10.1073/
pnas.0808046105
87. Budke B, Lv W, Kozikowski AP, Connell PP. Recent developments
using small molecules to target RAD51: how to best modulate
RAD51 for anticancer therapy? ChemMedChem 2016; 11: 2468-73.
https://doi.org/10.1002/cmdc.201600426
88. Pinder J, Salsman J, Dellaire G. Nuclear domain ‘knock-in’screen
for the evaluation and identification of small molecule enhancers
of CRISPR-based genome editing. Nucleic Acids Res 2015; 43:
9379-92. https://doi.org/10.1093/nar/gkv993
89. Pérez-Benavente B, Farràs R. Cell synchronization techniques to
study the action of CDK inhibitors. Methods Mol Biol 2016; 1336:
85-93. https://doi.org/10.1007/978-1-4939-2926-9_8
90. Rivera-Torres N, Strouse B, Bialk P, Niamat RA, Kmiec EB. The
position of DNA cleavage by TALENs and cell synchronization
influences the frequency of gene editing directed by singlestranded oligonucleotides. PLoS One 2014; 9: e96483. https://doi.
org/10.1371/journal.pone.0096483
91. Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed
human genome engineering by controlled timing of CRISPR/Cas9
delivery. Elife 2014; 3: e04766. https://doi.org/10.7554/eLife.04766
92. Tsakraklides V, Brevnova E, Stephanopoulos G, Shaw AJ. Improved
gene targeting through cell cycle synchronization. PLoS One 2015;
10: e0133434. https://doi.org/10.1371/journal.pone.0133434
93. Brachman EE, Kmiec EB. Gene repair in mammalian cells is
stimulated by the elongation of S phase and transient stalling of
replication forks. DNA Repair (Amst) 2005; 4: 445-57. https://doi.
org/10.1016/j.dnarep.2004.11.007
94. Wienert B, Nguyen DN, Guenther A, Feng SJ, Locke MN, Wyman
SK, et al. Timed inhibition of CDC7 increases CRISPR-Cas9
mediated templated repair. Nat Commun 2020; 11: 2109. https://
doi.org/10.1038/s41467-020-15845-1
95. Fernandez-Garcia B, Casado P, Prado MA, Ugarte-Gil LJ, Artime
N, Cabal-Hierro L, et al. Proteomic analysis of annexin A2
phosphorylation induced by microtubule interfering agents and
kinesin spindle protein inhibitors. J Proteome Res 2010; 9: 4649-60.
https://doi.org/10.1021/pr100377v
96. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular
mechanisms of indirubin and its derivatives: novel anticancer
molecules with their origin in traditional Chinese phytomedicine.
J Cancer Res Clin Oncol 2004; 130: 627-35. https://doi.org/10.1007/
s00432-004-0579-2
97. Rahman SH, Bobis-Wozowicz S, Chatterjee D, Gellhaus K, Pars
K, Heilbronn R, et al. The nontoxic cell cycle modulator indirubin
augments transduction of adeno-associated viral vectors and zincfinger nuclease-mediated gene targeting. Hum Gene Ther 2013; 24:
67-77. https://doi.org/10.1089/hum.2012.168
98. Moehle EA, Rock JM, Lee Y-L, Jouvenot Y, DeKelver RC, Gregory
PD, et al. Targeted gene addition into a specified location in the
human genome using designed zinc finger nucleases. Proc Natl
Acad Sci U S A 2007; 104: 3055-60. https://doi.org/10.1073/
pnas.0611478104
99. Ebrahimi V, Hashemi A. Challenges of in vitro genome editing
with CRISPR/Cas9 and possible solutions: A review. Gene 2020;
753: 144813. https://doi.org/10.1016/j.gene.2020.144813
100. Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M,
et al. Rapid and highly efficient mammalian cell engineering via
Cas9 protein transfection. J Biotechnol 2015; 208: 44-53. https://
doi.org/10.1016/j.jbiotec.2015.04.024
101. Yang H, Ren S, Yu S, Pan H, Li T, Ge S, et al. Methods Favoring
Homology-Directed Repair Choice in Response to CRISPR/Cas9
Induced-Double Strand Breaks. Int J Mol Sci 2020; 21:6461. https://
doi.org/10.3390/ijms21186461
102. Charpentier M, Khedher AHY, Menoret S, Brion A, Lamribet
390

BioImpacts, 2022, 12(4), 371-391

103.

104.

105.

106.

107.
108.

109.

110.

111.

112.

113.
114.

115.

116.

117.

118.
119.

K, Dardillac E, et al. CtIP fusion to Cas9 enhances transgene
integration by homology-dependent repair. Nat Commun 2018; 9:
1133. https://doi.org/10.1038/s41467-018-03475-7
Tran NT, Bashir S, Li X, Rossius J, Chu VT, Rajewsky K, et al.
Enhancement of Precise Gene Editing by the Association of Cas9
With Homologous Recombination Factors. Front Genet 2019; 10:
365. https://doi.org/10.3389/fgene.2019.00365
Tomimatsu N, Mukherjee B, Harris JL, Boffo FL, Hardebeck
MC, Potts PR, et al. DNA-damage-induced degradation of EXO1
exonuclease limits DNA end resection to ensure accurate DNA
repair. J Biol Chem 2017; 292: 10779-90. https://doi.org/10.1074/
jbc.M116.772475
Jayavaradhan R, Pillis DM, Goodman M, Zhang F, Zhang Y,
Andreassen PR, et al. CRISPR-Cas9 fusion to dominant-negative
53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target
sites. Nat Commun 2019; 10: 2866. https://doi.org/10.1038/s41467019-10735-7
Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D,
Mateos-Gomez PA, et al. Inhibition of 53BP1 favors homologydependent DNA repair and increases CRISPR-Cas9 genomeediting efficiency. Nat Biotechnol 2018; 36: 95-102. https://doi.
org/10.1038/nbt.4021
Hackley CR. A Novel Set of Cas9 Fusion Proteins to stimulate
Homologous Recombination: Cas9-HRs. CRISPR J 2020; 4: 253263. https://doi.org/10.1101/2020.05.17.100677
Ma L, Ruan J, Song J, Wen L, Yang D, Zhao J, et al. MiCas9 increases
large size gene knock-in rates and reduces undesirable on-target
and off-target indel edits. Nat Commun 2020; 11: 6082. https://doi.
org/10.1038/s41467-020-19842-2
Matsumoto D, Tamamura H, Nomura W. A cell cycle-dependent
CRISPR-Cas9 activation system based on an anti-CRISPR protein
shows improved genome editing accuracy. Commun Biol 2020; 3:
1-10. https://doi.org/10.1038/s42003-020-01340-2
Ali Z, Shami A, Sedeek K, Kamel R, Alhabsi A, Tehseen M, et al.
Fusion of the Cas9 endonuclease and the VirD2 relaxase facilitates
homology-directed repair for precise genome engineering in rice.
Commun Biol 2020; 3: 44. https://doi.org/10.1038/s42003-0200768-9
Ma M, Zhuang F, Hu X, Wang B, Wen XZ, Ji JF, et al. Efficient
generation of mice carrying homozygous double-floxp alleles using
the Cas9-Avidin/Biotin-donor DNA system. Cell Res 2017; 27:
578-81. https://doi.org/10.1038/cr.2017.29
Carlson-Stevermer J, Abdeen AA, Kohlenberg L, Goedland M,
Molugu K, Lou M, et al. Assembly of CRISPR ribonucleoproteins
with biotinylated oligonucleotides via an RNA aptamer for precise
gene editing. Nat Commun 2017; 8: 1711. https://doi.org/10.1038/
s41467-017-01875-9
Gu B, Posfai E, Rossant J. Efficient generation of targeted large
insertions by microinjection into two-cell-stage mouse embryos.
Nat Biotechnol 2018; 36: 632-7. https://doi.org/10.1038/nbt.4166
Lee K, Mackley VA, Rao A, Chong AT, Dewitt MA, Corn JE, et al.
Synthetically modified guide RNA and donor DNA are a versatile
platform for CRISPR-Cas9 engineering. Elife 2017; 6:e25312.
https://doi.org/10.7554/eLife.25312
Savic N, Ringnalda FC, Lindsay H, Berk C, Bargsten K, Li Y, et al.
Covalent linkage of the DNA repair template to the CRISPR-Cas9
nuclease enhances homology-directed repair. Elife 2018; 7:e33761.
https://doi.org/10.7554/eLife.33761
Aird EJ, Lovendahl KN, St Martin A, Harris RS, Gordon WR.
Increasing Cas9-mediated homology-directed repair efficiency
through covalent tethering of DNA repair template. Commun Biol
2018; 1: 54. https://doi.org/10.1038/s42003-018-0054-2
Ling X, Xie B, Gao X, Chang L, Zheng W, Chen H, et al. Improving
the efficiency of precise genome editing with site-specific Cas9oligonucleotide conjugates. Sci Adv 2020; 6: eaaz0051. https://doi.
org/10.1126/sciadv.aaz0051
Nunez JK, Harrington LB, Doudna JA. Chemical and Biophysical
Modulation of Cas9 for Tunable Genome Engineering. ACS Chem
Biol 2016; 11: 681-8. https://doi.org/10.1021/acschembio.5b01019
Pruett-Miller SM, Reading DW, Porter SN, Porteus MH.

Small molecules and modified CRISPR-Cas9 tools for accurate gene editing

120.

121.
122.
123.
124.

125.
126.

127.

128.

129.

130.

131.
132.

133.

134.

Attenuation of zinc finger nuclease toxicity by small-molecule
regulation of protein levels. PLoS Genet 2009; 5: e1000376. https://
doi.org/10.1371/journal.pgen.1000376
Davis KM, Pattanayak V, Thompson DB, Zuris JA, Liu DR. Small
molecule-triggered Cas9 protein with improved genome-editing
specificity. Nat Chem Biol 2015; 11: 316-8. https://doi.org/10.1038/
nchembio.1793
Vartak SV, Raghavan SC. Inhibition of nonhomologous end joining
to increase the specificity of CRISPR/Cas9 genome editing. FEBS J
2015; 282: 4289-94. https://doi.org/10.1111/febs.13416
Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt
FW. DNA repair, genome stability, and aging. Cell 2005; 120: 497512. https://doi.org/10.1016/j.cell.2005.01.028
Klein HL. The consequences of Rad51 overexpression for normal
and tumor cells. DNA Repair (Amst) 2008; 7: 686-93. https://doi.
org/10.1016/j.dnarep.2007.12.008
Zhang W, Chen Y, Yang J, Zhang J, Yu J, Wang M, et al. A
high-throughput small molecule screen identifies farrerol as a
potentiator of CRISPR/Cas9-mediated genome editing. Elife 2020;
9: e56008. https://doi.org/10.7554/eLife.56008
Wu Y, Yang L, Chang T, Kandeel F, Yee JK. A Small MoleculeControlled Cas9 Repressible System. Mol Ther Nucleic Acids 2020;
19: 922-32. https://doi.org/10.1016/j.omtn.2019.12.026
Bayat H, Modarressi MH, Rahimpour A. The Conspicuity of
CRISPR-Cpf1 System as a Significant Breakthrough in Genome
Editing. Curr Microbiol 2018; 75: 107-15. https://doi.org/10.1007/
s00284-017-1406-8
Li W, Chan C, Zeng C, Turk R, Behlke MA, Cheng X, et al. Rational
Design of Small Molecules to Enhance Genome Editing Efficiency
by Selectively Targeting Distinct Functional States of CRISPRCas12a. Bioconjug Chem 2020; 31: 542-6. https://doi.org/10.1021/
acs.bioconjchem.0c00062
Xu D, Cai Y, Tang L, Han X, Gao F, Cao H, et al. A CRISPR/Cas13based approach demonstrates biological relevance of vlinc class of
long non-coding RNAs in anticancer drug response. Sci Rep 2020;
10: 1794. https://doi.org/10.1038/s41598-020-58104-5
Rauch S, He E, Srienc M, Zhou H, Zhang Z, Dickinson BC.
Programmable RNA-Guided RNA Effector Proteins Built from
Human Parts. Cell 2019; 178: 122-34 e12. https://doi.org/10.1016/j.
cell.2019.05.049
Rauch S, Jones KA, Dickinson BC. Small Molecule-Inducible
RNA-Targeting Systems for Temporal Control of RNA Regulation.
ACS Cent Sci 2020; 6: 1987-96. https://doi.org/10.1021/
acscentsci.0c00537
Dasgupta I, Flotte TR, Keeler AM. CRISPR/Cas-Dependent and
Nuclease-Free In Vivo Therapeutic Gene Editing. Hum Gene Ther
2021; 32: 275-93. https://doi.org/10.1089/hum.2021.013
Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, et al. In
vivo genome editing restores haemostasis in a mouse model of
haemophilia. Nature 2011; 475: 217-21. https://doi.org/10.1038/
nature10177
Anguela XM, Sharma R, Doyon Y, Miller JC, Li H, Haurigot V,
et al. Robust ZFN-mediated genome editing in adult hemophilic
mice. Blood 2013; 122: 3283-7. https://doi.org/10.1182/
blood-2013-04-497354
Wang L, Yang Y, Breton CA, White J, Zhang J, Che Y, et al. CRISPR/

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

Cas9-mediated in vivo gene targeting corrects hemostasis in
newborn and adult factor IX–knockout mice. Blood 2019; 133:
2745-52. https://doi.org/10.1182/blood.2019000790
Stephens CJ, Lauron EJ, Kashentseva E, Lu ZH, Yokoyama WM,
Curiel DT. Long-term correction of hemophilia B using adenoviral
delivery of CRISPR/Cas9. J Control Release 2019; 298: 128-41.
https://doi.org/10.1016/j.jconrel.2019.02.009
Guan Y, Ma Y, Li Q, Sun Z, Ma L, Wu L, et al. CRISPR/Cas9‐
mediated somatic correction of a novel coagulator factor IX gene
mutation ameliorates hemophilia in mouse. EMBO Mol Med 2016;
8: 477-88. https://doi.org/10.15252/emmm.201506039
Laoharawee K, DeKelver RC, Podetz-Pedersen KM, Rohde M,
Sproul S, Nguyen H-O, et al. Dose-dependent prevention of
metabolic and neurologic disease in murine MPS II by ZFNmediated in vivo genome editing. Mol Ther 2018; 26: 1127-36.
https://doi.org/10.1016/j.ymthe.2018.03.002
Yin H, Song C-Q, Dorkin JR, Zhu LJ, Li Y, Wu Q, et al. Therapeutic
genome editing by combined viral and non-viral delivery of
CRISPR system components in vivo. Nat Biotechnol 2016; 34: 32833. https://doi.org/10.1038/nbt.3471
Shao Y, Wang L, Guo N, Wang S, Yang L, Li Y, et al. Cas9-nickase–
mediated genome editing corrects hereditary tyrosinemia in
rats. J Biol Chem 2018; 293: 6883-92. https://doi.org/10.1074/jbc.
RA117.000347
Bjursell M, Porritt MJ, Ericson E, Taheri-Ghahfarokhi A, Clausen
M, Magnusson L, et al. Therapeutic genome editing with CRISPR/
Cas9 in a humanized mouse model ameliorates α1-antitrypsin
deficiency phenotype. EBioMedicine 2018; 29: 104-11. https://doi.
org/10.1016/j.ebiom
Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR,
Hawkins RD, et al. Muscle-specific CRISPR/Cas9 dystrophin
gene editing ameliorates pathophysiology in a mouse model for
Duchenne muscular dystrophy. Nat Commun 2017; 8: 14454.
https://doi.org/10.1038/ncomms14454
Lee K, Conboy M, Park HM, Jiang F, Kim HJ, Dewitt MA, et al.
Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA
in vivo induces homology-directed DNA repair. Nat Biomed Eng
2017; 1: 889-901. https://doi.org/10.1038/s41551-017-0137-2
Cai Y, Cheng T, Yao Y, Li X, Ma Y, Li L, et al. In vivo genome editing
rescues photoreceptor degeneration via a Cas9/RecA-mediated
homology-directed repair pathway. Sci Adv 2019; 5: eaav3335.
https://doi.org/10.1126/sciadv.aav3335
Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, et al. A dual
AAV system enables the Cas9-mediated correction of a metabolic
liver disease in newborn mice. Nat Biotechnol 2016; 34: 334-8.
https://doi.org/10.1038/nbt.3469
Wang L, Yang Y, Breton C, Bell P, Li M, Zhang J, et al. A mutationindependent CRISPR-Cas9–mediated gene targeting approach to
treat a murine model of ornithine transcarbamylase deficiency. Sci
Adv 2020; 6: eaax5701. https://doi.org/10.1126/sciadv.aax5701
Schuh RS, Poletto É, Pasqualim G, Tavares AMV, Meyer FS, Gonzalez
EA, et al. In vivo genome editing of mucopolysaccharidosis I mice
using the CRISPR/Cas9 system. J Control Release 2018; 288: 23-33.
https://doi.org/10.1016/j.jconrel.2018.08.031

BioImpacts, 2022, 12(4), 371-391

391

